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The opioid crisis in the United States was declared a public health emergency due to 
escalating and untoward human, financial, and systemic consequences and effects on the 
nation. Opioid use disorder (OUD) comprising opioid abuse and dependence is devastating 
because of its associated chronic relapsing nature, overutilization of healthcare services, 
rising morbidity and mortality rates, and high cost of care. Efforts to address this have not 
made significant positive impacts. It is thus imperative to reassess the influence of factors 
associated with OUD.   
This study answered the question, what patient-, hospital-, and state-level policy 
factors were associated with prevalence of diagnosing and treating OUD in U.S. emergency 
departments (ED), since the ED which were usually first point-of-contact with the healthcare 
system by patients with OUD witnessed significantly increased visits related to nonmedical 
use of opioids. 
A retrospective secondary data analysis of the cross-sectional Nationwide Emergency 
Department Sample of patients 12 years and older from January 1 to December 31, 2016; 
 
 
ASAM state reports; SAMHSA Office of Policy, Planning and Innovation State Medicaid 
coverage reports; and KFF report on opioid epidemic was performed. Outcome variable was 
prevalence of diagnosing and treating OUD in the ED. Primary predictor variable was OUD 
condition, and covariates included, patient characteristics – primary payer, annual median 
income, patient location, and ED event; hospital characteristics – control/ownership, region, 
and designation; and state-level policy characteristics – medication-assisted treatment (MAT) 
policy, MAT medication coverage, Medicaid expansion, and Medicaid section 1115 
behavioral health waiver statuses. Descriptive statistics was reported for all variables. 
Pearson’s chi-squared was test used to determine statistically significant differences between 
opioid abuse and opioid dependence diagnosis. Hierarchical linear regression model (HLM) 
was used to estimate association between outcome and predictor variables. 
In total, 32,680,232 ED visits in 953 hospitals across 35 states and District of 
Columbia which when generalized to the entire United States amounted to 144,842,742 visits 
to the ED in 4,639 hospitals across the 50 states including the District of Columbia were 
analyzed. The total number of opioid-related incidents to the ED was 1,623,490. The overall 
prevalence of any opioid-related incident was 1.12% while overall prevalence of diagnosis 
and treatment of uncomplicated OUD in U.S. ED was 0.5%. Significant regional disparities 
existed in state-level opioid policies, prevalence of uncomplicated OUD and other 
characteristics influencing treatment of OUD in U.S. ED. Opioid dependence patients 
(55.6%) were preponderantly of upper-lower income class, micropolitan residents, covered 
by Medicare; admitted to same hospital they presented, attended to largely in privately-
owned not-for-profit ED, in micropolitan areas, and in Southern and Western U.S. Opioid 
 
 
abuse patients (44.4%) were predominantly of lower-lower income status, metropolitan 
dwellers, Medicaid covered; presented commonly to privately-owned not-for-profit ED, in 
metropolitan locations, and in Northeastern and Midwestern U.S. Combined, patient and 
hospital-level policy characteristics accounted for 25.4% (R2=0.254, Adj. R2=0.254, F 
change (3,734618)=31937.906, p<0.0001) of variance in prevalence of treating OUD in ED. 
Patient characteristics only accounted for 15.6% (R2=0.156, Adj. R2=0.156, 
F(5,734621)=27245.686, p<0.0001) and hospital characteristics only for 9.7% (R2 
change=0.097, F(3,734618)=31937.906, p<0.0001) of the variance. Proportion of variance 
accounted for by each predictor variable was, control/ownership of hospital (9.67%), patient 
location (6.35%), annual median income (1.44%), hospital designation (1.21%), OUD 
diagnosis (0.20%), primary payer (0.04%), region of hospital (0.02%), and ED event 
(0.008%). 
Patient and hospital level characteristics significantly influenced prevalence of 
treating OUD in U.S. ED. Hospital-level characteristics contributed more that patient-level 
characteristics. A socioecological approach, which ensures an integrated and holistic method, 
is required to understand factors influencing OUD with the view to developing innovative 
policies and programs that can positively and significantly address the opioid crisis.  
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BACKGROUND 
Introduction 
This dissertation will determine the prevalence of emergency care of opioid use disorder 
in the United States population 12 years and older with a view to guiding drug policy and 
program implementation. 
 The devastating effects of opioids in developed and developing nations is no longer news. 
What may be news is the context in which the problem is framed which invariably affects 
perceptions of the scope of the problem and how it is addressed subsequently. The President of 
the United States, under federal law declared the opioid crisis in America as a national public 
health emergency on October 26, 2017 (The White House, 2017).  
Current research on opioids focuses on prescribing and dispensing practices 
(Jayawardhana et al, 2018; Cochran et al, 2017; Dowell et al, 2016); treatment of specific 
conditions such as chronic pain, back disorders, arthritis, inflammatory bowel disease (Hayes et 
al, 2018; Cohen-Mekelburg et al,2018); prevention of opioid overdoses (Peglow et al, 2018; 
Huhn et al, 2018; McGinty et al, 2018; Lynch et al, 2017); treatment of substance use disorders 
especially opioid overdoses (Zhu et al, 2018; Vipler et al, 2018; Garland et al, 2018; Brinkley-
Rubinstein et al, 2018; Borodovsky et al, 2018; Heslin et al, 2017; Mosher et al, 2017); 
adherence/non-adherence to treatment (Lo-Ciganic et al, 2018); prevalence of specific conditions 
(e.g. obesity, HIV, mental health disorders) among opioid use disorder (OUD) populations (Hu 
et al, 2018; Shrestha et al, ;2018; Cochran et al, 2017); substance use disorders including opioids 
(Serdarevic et al, 2018; Hawk et al, 2018); cost of providing treatment (Chang et al, 2018; 
Burgos et al, 2018; Xie et al, 2014; Chandwani et al, 2013); and molecular and pharmacogenetic 
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basis of treating substance use disorders including OUD (Fang etal, 2018; Schroeder et al, 2018, 
Crist et al, 2018; Laudenbach et al, 2018).  
Furthermore, recent opioid research has focused on community-based populations (Serdarevic et 
al, 2018; Cochran et al, 2017), specific populations such as children and adolescents 12-17 years 
old (Borodovsky et al, 2018; Levy et al., 2016; Wu et al., 2016; Hadland et al., 2016; Xie et al, 
2014; Muhuri et al., 2013, SAMHSA, 2013a), women (Hayes et al, 2018; Serdarevic et al, 2018), 
pregnant women (Jayawardhana et al, 2018; Peglow et al, 2018), incarcerated individuals 
(Brinkley-Rubinstein et al, 2018), individuals enrolled in clinical trials (Hu et al, 2018); and 
privately insured individuals (Sun et al, 2017). 
The sites of these studies have been mainly inpatient-based (Zhu et al, 2018; Peglow et 
al, 2018; Cohen-Mekelburg et al, 2018; Heslin et al, 2017; Mosher et al, 2017; Gaither et al, 
2016), a combination of inpatient-based and emergency department visits (Peterson et al, 2018; 
Tedesco et al, 2017; Wu et al., 2016) or ambulatory clinics only (Peglow et al, 2018; Wu et al., 
2016). Few have focused on patients with OUD visiting the emergency department only (Hawk 
et al, 2018; Wu et al., 2016; Xie et al, 2014; Chandwani et al, 2013). 
This research fills an important gap in providing current estimates of the prevalence of 
diagnosing and treating OUD in emergency departments (ED) in the United States. The 
implications of this research include guiding policymaking, resource allocation, program 
planning and implementation regarding management of OUD in the ED (Burgos et al, 2018; 
Friedmann et al, 2017; Molfenter et al, 2017; Ford et al, 2017). 
Why study disease prevalence? 
 Estimating burden of disease specifically prevalence may potentially influence health 
policy development and implementation regionally and globally (Degenhardt et al, 2014a). 
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How does prevalence estimations influence policy? 
 Prevalence of disease influence policy by driving change and leading to meaningful 
differences in health outcomes (Aldrich et al, 2015). 
Literature Review 
In this review of the literature, the timeline of the opioid crisis in the United States is 
highlighted, opioid crisis as a public health emergency is discussed, the opioid crisis is evaluated 
using the quadruple aim framework and the significance of opioid use disorder is emphasized. 
 Advocacy for better treatment of pain in the United States started in 1991 (Tsang et al., 
2008). This resulted in introduction of opioid analgesics (pain relievers) to manage both acute 
and chronic pain. Opioids are a class of drugs consisting of Schedule II analgesics such as 
codeine, oxycodone, hydrocodone, morphine, and legally prescribed fentanyl; and the Schedule I 
drug – heroin – considered illicit. The achievement of pain relieving effects of opioids are 
through stimulation of neurotransmitter production in the central nervous system and 
gastrointestinal tract (National Institute on Drug Abuse, 2015). When taken as prescribed by 
healthcare providers and over a short period, opioid analgesics are essentially safe. However, 
because of the added euphoric effects, opioids may not be taken as prescribed, taken in quantities 
lager than prescribed or taken without being prescribed (National Institute on Drug Abuse, 
2015). Notwithstanding legally prescribed or illicitly obtained, opioids readily result in abuse 
leading to opioid use disorder (OUD) such as dependency and addiction. Consequences of 
iatrogenic or recreational long-term use of opioids include physical and/or psychological 
dependence, overdose, and death (National Institute on Drug Abuse, 2015). Specifically, 
problematic uses of opioids are categorized and defined as (1) Misuse – “opioid use contrary to 
the directed or prescribed pattern of use, regardless of the presence or absence of harm or 
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adverse effects”. (2) Abuse – “intentional use of the opioid for a nonmedical purpose, such as 
euphoria or altering one’s state of consciousness”. (3) Addiction – “pattern of continued use with 
experience of, or demonstrated potential for, harm” which may include inability to control use of 
the drug, habitual drug use, constant drug use in the face of harm, and insatiable craving 
(Naliboff et al., 2011; Smith et al., 2013; Butler, 2013; Sullivan, 2013; Vowles et al., 2015). 
There is controversy over using the term “addiction” or “dependence” (O’Brien et al., 2006; 
Regier et al, 2013). However, in the American Psychiatric Association Diagnostic and Statistical 
Manual of Mental Disorders, fifth Edition (DSM-5) Classification, “dependence” is the preferred 
term. According to the DSM-5 classification, the two disorders, opioid abuse and opioid  
dependence, have now been combined into a single term – Opioid Use Disorder (Hartney & 
Gans, 2008; Regier et al, 2013). 
 An unintended consequence of the advocacy efforts and subsequent escalation in pain 
treatment of the early 1990s was an increase over four times of prescription opioid induced 
overdose mortality between 1999 and 2018 (Seth et al., 2018). A proportion of opioid users 
began their dependence on the drug following legal prescription of opioids by healthcare 
providers (Schoenfeld et al, 2017). Furthermore, attributed to use of prescription opioids was the 
initiation of drug abuse in 80% of heroin users (Muhuri et al., 2013). Over 116 million 
individuals are living with chronic pain in the United States (Seth et al., 2018). Concerning 
chronic pain treatment, between 21% and 29% percent of individuals on prescription opioids 
ultimately misuse their medication with 8% to 12% becoming addicted (Vowles et al., 2015). 
Consequently, the United States is currently experiencing a significant opioid misuse crisis 
(Trasolini et al, 2018). 
Opioid Crisis in America 
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Timeline of opioid analgesic use and opioid crisis 
Pre 1800 to 1800 – Prior to 1800, clinicians viewed pain as part of human existence and 
experience. It was considered a result of aging (Meldrum, 2003a). As such, not regulating use of 
cocaine and opioids in this era resulted in pervasive marketing and prescription for various 
illnesses from toothache to diarrhea (Clarke et al, 2016). 
1801 to 1979 – During the 19th century, opioids were used as standard treatment for acute 
and recurrent pain. In 1804, Friedrich Wilhelm Sertürner produced morphine from crude opium 
(Schmitz, 1985). By the 1820s, Germany had commenced industrial production of morphine 
followed a decade later by the United States. In 1855, Alexander Wood invented the technique of 
using a hypodermic syringe and fine bore needle to deliver morphine subcutaneously to pain 
sites. The convenience of this mode of ensuring pain relieve may have heralded overuse of 
morphine for analgesia (Howard-Jones, 1947). Furthermore, non-regulation and easily available 
over the counter formulations of opium and alcohol-based preparations as pills, liquids and 
powders made self-medication convenient. This trend continued into the 1870s during which 
physicians started observing the “repeated indulgence inducing bodily and mental prostration 
and mental perversion” associated with “the morphine habit” or “narcomania” of using morphine 
(Kerr, 1894). Germany’s Bayer Company started marketing diacetylated morphine pills for 
treatment of cough under the trade name of “Heroin” in 1898. This diacetylated morphine 
introduced as less habit-forming was an alternative to morphine. However, by 1910, diacetylated 
morphine pills were being crushed into powder and inhaled for concentrated high by the young 
working-class in the United States. The rising trend of morphine (heroin) addiction due to legal 
and illicit use resulted in overwhelming support of the Harrison Narcotic Control Act of 1914.  
 
                                                                                                                           9 
 
A consequence of this Act was “opiophobia”, where both physicians and patients avoided 
prescribing and using opioid analgesics respectively. (Meldrum, 2003a; Meldrum, 2003b; Jones 
et al., 2018). Thus, by the 1920s, patients with unexplained pain were categorized as deluded, 
malingers or abusers looking for a “heroin fix” while into the 1950s, patients with cancer were 
encouraged to self-wean off opioids (Schiffrin, 1956). Opiophobia continued into the second half 
of the twentieth century (Meldrum, 2003a; Jones et al., 2018). Therefore, under-treatment of 
pain, another consequence, led to advocacy to bring awareness to this issue especially following 
a 1973 Annals of Internal Medicine publication by Richard Marks and Edward Sachar (Marks & 
Sachar, 1973). 
 1980 to 1989 – Generally, in the 1980s, several physicians were fearful of prescribing 
opioids in spite of an extensively cited article suggesting opioid-induced addiction was rare with 
opioids taken for short-term pain (Porter & Jick, 1980). Specifically, John Morgan in 1985 in the 
United States and Michael Zenz and Anne Willweber-Strumpf in 1992 in Europe stressed the 
issue of less reliance on opioid analgesics and resultant under-treatment of pain. This was due to 
physicians’ conflict arising from their desire to relieve adequately the pain of patients and their 
fear of inducing addiction in these patients (Morgan, 1985; Zenz & Willweber-Strumpf, 1993). 
In spite of education, clinical guidelines, and advocacy to change the perceptions, attitudes, and 
believes of physicians towards prescribing opioids for pain management, practice had not change 
(National Institutes of Health, 1986; American Pain Society, 1987, WHO, 1986, 1996; Carr & 
Jacox, 1997). Thus, due to the attendant problem of underassessment and under-treatment of 
pain, opinion leaders and experts in the field called for improved assessment, robust and more 
vigorous treatment methods to address the problem of inadequate pain management including the 
use of opioids (Max, 1990, Baker, 2017). 
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 1990 to 1999 – Following the work of Morgan and Zenz and Willweber-Strumpf, the 
clear call for a change in the strategy for assessment and management of pain intensified in the 
1990s. The American Pain Society through its then president, Dr. Mitchell Max was at the 
forefront of these efforts. He wrote an editorial in Annals of Internal Medicine criticizing the lack 
of improvement in assessment and treatment of pain over the preceding two decades (Max, 
1990). In addition, education, advocacy, and clinical guidelines in the prior decade from 
Ubaker.S. Agency for Health Care Policy and Research, American Pain Society, and World 
Health Organization had not worked (National Institutes of Health, 1986; American Pain 
Society, 1987, WHO, 1986, 1996; Carr & Jacox, 1997). Reasons proffered for this failure 
included patients not informing their healthcare providers about their pain, nurses’ inability to 
adjust pain medication doses, and physicians’ reluctance to prescribe opioids. In taking a new 
approach to pain management, Dr. Max stressed then conventional wisdom that “therapeutic use 
of opiate analgesics rarely results in addiction”. He thus recommended (1) making pain “visible”. 
(2) Giving practitioners “bedside” tools for change to guide physicians and nurses to initiate and 
modify analgesic treatments. (3) Assuring patients a place in the “communications loop”. (4) 
Increasing clinician accountability by developing “quality assurance guidelines”, improving care 
systems, and assessing patient satisfaction. (5) Facilitating innovation and exchange of ideas. (6) 
Working with narcotics control authorities to encourage therapeutic opiate use.  
Consequently, in response to greater awareness of pain levels of patients and more therapeutic 
use of opioids, and prior to acknowledgement of the opioid crisis, healthcare providers were 
motivated to treat pain generously with opioid analgesics (Max, 1990; Baker, 2017). The 
resultant effect was pressure to prescribe opioid analgesics every time pain was reported 
(Trasolini et al, 2018). As such, pain was promoted as the “fifth vital sign” and an “enemy that 
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needed to be eradicated” (Baker, 2017). For instance, in 1999, California’s legislature voted for 
an act necessitating that facilities record pain levels together with routine vital sign 
measurements (Escutia, 1999). 
In 1995, the Food and Drug Administration approved OxyContin® (Oxycodone) for treatment of 
pain. Misleadingly and aggressively marketed as a non-addicting opioid analgesic, OxyContin 
quickly developed into a widely prescribed pain reliever. Consequently, there was a 153% rise in 
opioid analgesics prescribing between 1990 and 1999 from 76 to 116 million prescriptions 
respectively (Baker, 2017). In many ways, the discovery that OxyContin® was an opioid with a 
high risk for addiction and dependence may have driven the second wave of the opioid crisis 
(Van Zee, 2009).  
 2000 to 2009 – The Joint Commission in collaboration with the University of Wisconsin-
Madison School of Medicine and experts nationwide started to develop its first pain standards in 
1997 and completed it in 2000. The Joint Commission initiative followed the advocacy by 
American Pain Society for novel quality assurance standards for acute and cancer pain, and as a 
result of the overall paucity of knowledge regarding pain management, and misunderstandings 
concerning tolerance and addiction to drugs (American Pain Society, 1987; Institute of Medicine, 
1987; Campbell, 1995). Part of the requirements of the Joint Commission’s standards was that all 
healthcare organizations were to assess systematically and quantitatively every patient for pain 
(Morone & Weiner, 2013; Barker, 2017). Furthermore, the United States Congress declared a 
“Decade on Pain Control and Research,” from 2001 to 2011. Following this, there was increase 
in opioid analgesics prescribing. Equally, due to public health research efforts, there were 
increasing reports of misuse, addiction, and deaths due to opioid-related overdoses (Interagency 
 
                                                                                                                           12 
 
Pain Research Coordinating Committee, 2015). All these coincided with when OxyContin® had 
become a leading drug of abuse in the United States in 2004 (Van Zee, 2009). 
 2010 to present – In 2011, the prescription of opioid analgesics had risen to 219 million 
prescriptions – a 288% and 189% rise from 1990 and 1999 levels respectively. It was 255 
million prescriptions in 2012 (335%, 219%, and 116% rise from 1990, 1999, and 2011 levels 
respectively) (Baker, 2017; Centers for Disease Control and Prevention, 2018b). By 2015, over 
33,000 Americans had died from opioid overdose due to prescription opioids, heroin, and 
illegally manufactured synthetic opioid – Fentanyl (Centers for Disease Control and 
Prevention/National Center for Health Statistics, 2018). Reported in 2015 in the United States 
were approximately 2 million cases of substance use disorders associated with prescription 
opioids and 591,000 cases of heroin use disorder not mutually exclusive from the former (Center 
for Behavioral Health Statistics and Quality, 2016).  
The third wave of the opioid crisis ushered in in 2013 was due to synthetic opioids such as 
fentanyl. By 2016, mortality related to illegally manufactured fentanyl and not diverted medical 
fentanyl and associated drugs was over 20,000. Illegally manufactured fentanyl was being used 
to adulterate or as a replacement for other drugs of abuse (Ciccarone, 2017; Dismukes, 2018; Liu 
et al., 2018).  
In 2016, Centers for Disease Control and Prevention (CDC) provided comprehensive guidelines 
for best practices regarding prescribing opioids for non-cancer related chronic pain, in an effort 
to curb risks associated with prescribing opioid analgesics and to maximize available benefits 
accruable from different pain treatment alternatives (Dowell et al., 2016). Some of these 
recommendations include using non-opioid treatment regimens as the first line of approach to 
treating non-cancer related chronic pain; and using opioid analgesics only following cautious 
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pain control assessment and constant evaluations for their continued indication (Dowell et al., 
2016). Figure 1 shows a timeline summary of opioid analgesic use and opioid crisis in America. 
Figure 1. Timeline of Opioid Analgesic Use and Opioid Crisis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opioid Crisis as a Public Health Emergency 
 The opioid crisis in the United State was declared a public health emergency (PHE) on 
October 26, 2017 by Eric D. Hargan, then Acting Secretary of Health and Human Services 
(Hargan, 2017; Health and Human Services, 2017). This declaration made at the behest of the 
President and following necessary consultation with public health officials was extended through 
April 24, 2018 (Health and Human Services, 2017; Haffajee et al., 2018). The declaration of the 
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opioid crisis in America as a public health emergency was necessary due to the escalating and 
untoward consequences and impacts of the crisis on the nation (Haffajee et al., 2014). Prior to 
the declaration, over 190 deaths per day in the United Sates were due to drug overdoses. Of 
these, over 130 deaths per day were the result of opioid overdoses (Centers for Disease Control 
and Prevention/National Center for Health Statistics, 2018). In addition, between 1999 and 2017, 
there was a 256% increase in age-adjusted rate of drug overdose mortality from 6.1 to 21.7 per 
100,000 (Hedegaard et al., 2018). Furthermore, in fiscal year 2017 ending September 30, 
approximately $900 million had been invested on training, education, treatment and recovery, 
and other support services for opioid-related conditions by the United States’ Department of 
Health and Human Services (Health and Human Services, 2017). As such, declaring the crisis a 
public health emergency (PHE) was intended to, allow the federal government take legitimate 
actions devoid of legislative bureaucracy to address the opioid crisis, permit use of new funds or 
repurposing of existing funds to deal with the crisis, expedite ad hoc subject-matter expert 
appointments to proffer solutions, ensure collaboration with agencies such as the Drug 
Enforcement Agency to increase telemedicine access for opioid dependence treatment for 
specific patients requiring such services, and to ensure that HIV/AIDS programs have 
flexibilities that included managing associated opioid-related conditions (Haffajee et al., 2014; 
Health and Human Services, 2017). 
Opioid Crisis in context of the Quadruple Aim 
The Quadruple Aim is a modification to and expansion of the Triple Aim Framework of 
healthcare improvement by inclusion of a fourth dimension – Improving provider experience of 
care. The justification for including this fourth dimension is based on the argument that attaining 
a truly effective health system performing at optimal levels requires a satisfied, motivated, and 
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engaged healthcare workforce devoid of burnout (Bodenheimer & Sinsky, 2014; Sikka et al., 
2015; West, 2016). Triple Aim on the other hand, is a framework describing an approach to 
enhancing performance of health systems. The Triple Aim framework posits that improving 
performance of health systems through new systems designs must consider three interdependent 
dimensions (Triple Aim): 1) Improving care experience of patients; 2) Improving population 
health; and 3) Reducing per capita healthcare cost. The Institute for Healthcare Improvement 
(IHI) developed the Triple Aim framework (Institute of Healthcare Improvement, n.d; Berwick 
et al., 2008). 
Opioid crisis and individual experience of care 
An approach to evaluating the opioid crisis is to view it at the individual level as a 
person-specific problem, which influences individual experience of care. Prolonged use and/or 
use at higher doses of prescription opioids potentially increases risk of opioid use disorder, 
overdose, and death. Some of the individual patient-level person-specific factors shown to drive 
the opioid crisis include: previous history of substance abuse and mental health status (Ives et al. 
2006; Sullivan et al. 2010; Fischer et al. 2012); economic circumstances of individuals including 
employment and income (Case and Deaton, 2015; 2017). Over 30% of individuals in the United 
States suffer from acute or chronic pain (Johannes et al., 2010; Simon, 2012). The high 
prevalence of chronic pain coupled with its frequently debilitating effects underscores the reason 
for opioid analgesics being the most frequently prescribed category of medications in the United 
States (Centers for Disease Control and Prevention, 2012). Given the rising rates of patients 
progressing from use of opioid analgesics for treatment of pain to misuse and subsequent 
dependence, advocates are calling for more controlled prescribing of opioids. However, the 
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opioid crisis is a multi-faceted problem of which curbing prescribing rates is just one part 
(Patient Engagement HIT, 2018).  
Concerning chronic pain, prevalence is increasing in United States adults. Studies have 
estimated that the prevalence of chronic pain in U.S adults ranges between 11% and 40% 
(National Institute of Health, 2016). In 2012, 11.2% of adults in U.S experienced chronic pain 
(Nahin, 2015) which increased to 20.4% in 2016 (Dahlhamer et al., 2016). Living with chronic 
pain can rapidly develop into problems of quality of life. Since the pain affects the experience of 
patients during daily activities, it can limit their participation in daily routines including school, 
work, and social activities. However, long-tern treatment with opioids predisposes these patients 
to a higher risk misuse, dependence and progression to heroin addiction (Volkow et al., 2016).   
Adequately treating both acute (such as post-surgical pain) and chronic pain (such as 
non-cancer related chronic pain) is critical to a positive individual patient experience of care – 
including quality of care and satisfaction with care. Healthcare providers however find 
themselves put in a position of conflict between satisfactorily relieving patients’ pain, improving 
their experience of care, quality of life, and preventing misuse of and dependence on opioid 
analgesics. Thus, reconciliation between the current opioid crisis, treatment of pain, and ensuring 
patient satisfaction with care received puts healthcare providers in a difficult position (Morgan, 
1985; Zenz & Willweber-Strumpf, 1993; Patient Engagement HIT, 2018). Furthermore, efforts 
at addressing the opioid crisis by limiting supply may be depriving patients who rightfully need 
opioids from receiving life-sustaining treatment and for those on long-term treatment with 
opioids from legitimately filling their prescriptions (Nicholson, 2018; Schultz, 2018). This may 
ultimately result in lack of improved experience of care. 
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As such, a vital point to addressing the opioid crisis requires understanding the role of 
opioids in care of patients with pain. Treatment for pain in some patients may require opioid 
analgesics leading to improved satisfaction with care while others may benefit from alternative 
paint management options. On the other hand, patients need to understand how to use opioid 
analgesics responsibly while appreciating the risks associated with taking these medications. 
Therefore, patient and provider education is important in efforts to address the opioid crisis 
(Patient Engagement HIT, 2018). 
Opioid crisis and population health 
Another approach of framing the opioid crisis is as a population health problem. This 
potentially broadens the scope of the problem beyond the individual. This population health 
approach involves confronting root causes, trans-sectoral collaborations, eradicating inequalities 
in access to treatment, and tackling and decreasing racial biases and stigma (Gourevitch, 2018) 
compared to focusing more on individual experience of care or lack thereof. This approach 
ensures multi-pronged efforts to reversing the trend on the crisis and subsequently improving the 
health of populations. This in other words would require a systems approach to the opioid crisis 
((Martin et al., 2016); Martin & Laderman, 2016).  
There are demographic, socioeconomic, and healthcare-related characteristics associated 
with the opioid crisis. Demographic characteristic includes: (i) Race – predominantly Caucasian 
and/or African American. Socioeconomic characteristics include: (i) Poverty. (ii) 
Unemployment. (iii) Low educational attainment. Healthcare-related characteristics include: (i) 
Uninsured. (ii) High healthcare services utilization such as those suffering with chronic pain. 
(Ghertner & Groves, 2018; Karamouzian & Kerr, 2018; Keyes et al., 2014; Muhuri et al., 2013; 
Cicero et al., 2014; Vowles et al., 2015; Carlson et al., 2016; National Institute on Drug Abuse, 
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2018c; Guy et al., 2017; Webster et al., 2009; McDonald et al., 2012; Wennberg, 2011; 
McDonald & Carlson, 2014). There are however, four different types of patient sub-populations 
associated with the opioid crisis. These distinct but interdependent sub-populations include the: 
(1) naïve patient; (2) high-dose chronic use patient; (3) opioid-dependent, seeking within 
healthcare patient; and (4) opioid-dependent, seeking outside of healthcare patient (Martin et al., 
2016). Based on the risk factors above, approximately 21% to 29% of patients with chronic pain 
prescribed opioid eventually misuse the prescribed opioids. Eight percent to 12% ultimately 
develop opioid use disorder while about 4% to 6% of those misusing the prescribed opioids 
switch to using heroin (Muhuri et al., 2013; Cicero et al., 2014; Vowles et al., 2015; Carlson et 
al., 2016; National Institute on Drug Abuse, 2018c).  
To adequately address the opioid crisis and subsequently improve the health of 
populations, policy makers and health systems should make decisions and allocate resources that 
specifically target these populations. 
Opioid crisis and per capita cost of care 
Per capita cost – Regarding the opioid crisis, per capita cost of care refers to the average 
cost of caring for opioid use disorder per person or average cost of healthcare for opioid use 
disorder per member of the population (Institute of Healthcare Improvement, n.d; Berwick et al., 
2008). Total cost – The total cost of the opioid crisis to the United States is immense. This total 
cost includes: (1) tangible cost – such as healthcare, criminal justice, lost productivity cost; and 
(2) intangible cost – comprising cost to quality of life, emotional cost, and cost of pain/suffering 
endured (Brill & Ganz, 2018). In 2015, the total cost of the opioid crisis including mortality, 
healthcare, criminal justice and lost productivity costs to the United States economy was 2.8% of 
GDP and estimated to be $504 billion. This total cost of the opioid crisis is a combination of; (1) 
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mortality cost – consisting of value of statistical lives lost due to opioid overdoses – of $431.7 
billion (85.7%) and (2) non-mortality cost – consisting of average cost of non-fatal consequences 
of opioid use disorder – of $72.3 billion (14.3%) (Council of Economic Advisers, 2017). This 
total cost is over six to forty-eight times more than previously estimated cost of the crisis to the 
US economy (Birnbaum et al., 2006, Birnbaum et al., 2011, Florence et al., 2016). It is important 
to note that other prior estimated costs focused on estimating the cost of prescription opioids 
only. However, the current total cost of $504 billion is six to forty-eight times higher because it 
includes the cost of both prescription and illicit opioids; fatalities due to opioid overdoses have 
increased significantly; and value of lives lost were fully accounted for in the $504 billion 
estimate. In addition, there are geographical variations to the distribution of this cost that need to 
be accounted for at the federal, state and local levels when policies are being enacted to address 
the opioid crisis (Council of Economic Advisers, 2017; Brill & Ganz, 2018).   
In 2015 dollars, while total healthcare expenditures per capita by state of residence in the 
United States revealed a national average of $8,054.55, total health care expenditures per capita 
for states with the top five highest total per capita cost of the opioid crisis were all above the 
national average and within the top 20 highest health care expenditures per capita for that year. 
Specifically, West Virginia was 12th at 118% ($9,473.23) of national average; Washington, D.C. 
1st at 148% ($11,958.18); New Hampshire 9th at 119% ($9,600.38); Ohio 17th at 108% 
($8,722.34); and Maryland 19th at 106% ($8,612.21). For states with the top five lowest total per 
capita cost of opioid crisis, Iowa, Montana, and Nebraska had total health care expenditures per 
capita by state of residence above the national average while those for Mississippi and Texas 
were below national average. Specifically, Iowa was 25th at 101% ($8,209.73) of national 
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average; Mississippi 34th at 95% ($7,655.08); Texas 45th at 86% ($7,006.31); Montana 24th at 
102% ($8,230.76); and Nebraska 20th at 104% ($8,421.98). 
State-level total and non-mortality per capita cost of the opioid crisis are spatially 
distributed. In 2015, states with the top five highest total per capita cost of the opioid crisis 
included West Virginia – $4,378; Washington, D.C. – $3,657; New Hampshire – $3,640; Ohio – 
$3,385; and Maryland – $3,337. These states mostly in the Appalachian region are all in the 
eastern United States except for Ohio, which is in the Midwest. States with the top five lowest 
total per capita cost included Iowa – $705; Mississippi – $703; Texas – $653; Montana – $596; 
and Nebraska – $394. These states are in the Midwestern and southern United States. (Brill & 
Ganz, 2018). Similarly, states with the top five highest non-mortality per capita cost of the opioid 
crisis were Washington, D.C. – $493; New Hampshire – $360; Connecticut – $358; Washington 
– $331; and New York – $320. These states are all in the eastern United States except for 
Washington, which is in the west. States with the top five lowest non-mortality per capita cost 
were Texas – $144; Arkansas – $143; Mississippi – $138; Nebraska – $126; and Iowa – $118. 
These states are in the Midwestern and southern United States. (Brill & Ganz, 2018). 
Regarding states with the top five highest and lowest non-mortality per capita cost of the 
opioid crisis, health care expenditure per capita by state of residence not already mentioned were 
Connecticut 6th at 122% ($9,870.70) of national average, Washington 31st at 98% ($7,922.39), 
New York 9th at 121% ($9,789.61); and Arkansas 38th at 92% ($7,416.39) respectively in 2015. 
It is important to note here that health care expenditure per capita (also known as health spending 
per capita) is “spending for all privately and publicly funded personal health care services and 
products (hospital care, physician services, nursing home care, prescription drugs, and so on) by 
state of residence (aggregate spending divided by population)”. Where included hospital costs 
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represent total net revenue comprised of gross charges less contractual adjustments, bad debts, 
and charity care. Excluded from this total health care expenditure per capita are insurance 
program administration, research, and construction-related costs (Kaiser Family Foundation, 
2017b). 
Also, of significance is the percentage of total health care expenditure per capita by state 
of residence that both the total and non-mortality per capita cost of the opioid crisis constitute 
respectively. Concerning states with the top five highest total per capita cost of the opioid crisis, 
West Virginia’s opioid crisis comprises about 46%; Washington, D.C. 30%; New Hampshire 
37%; Ohio 38%; and Maryland 38% of the total health care expenditure per capita by state of 
residence respectively. For states with the top five lowest total per capita cost of opioid crisis, 
Iowa’s opioid crisis constitutes about 8%; Mississippi 9%; Texas 9%; Montana 7%; and 
Nebraska 4% of the total health care expenditure per capita by state of residence respectively. 
In relation to states with the top five highest non-mortality per capita cost of the opioid 
crisis, Washington, D.C.’s opioid crisis consist of  approximately 4%; New Hampshire 3%; 
Connecticut 3%; Washington 4%; and New York 3% of the total health care expenditure per 
capita by state of residence respectively. For states with the lowest non-mortality per capita cost 
of the opioid crisis, Texas was 2%; Arkansas 1%; Mississippi 1%; Nebraska 1%; and Iowa 1% 
of the total health care expenditure per capita by state of residence respectively. Table 1 shows 
the total health care expenditure per capita by state of residence, total per capita cost of the 
opioid crisis (as a percentage of the total health care expenditure per capita by state of residence), 
and non-mortality per capita cost of the opioid crisis (as a percentage of the total health care 
expenditure per capita by state of residence) of the top five states in the United States. 
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Table 1. Total Health Care Expenditure per Capita by State of Residence, Total per Capita Cost 
and Non-Mortality per Capita Cost of Opioid Crisis of Top Five States in United States. 
Top Five States 
Total Health 
Care 
Expenditure 
per Capita 
by State  
(a) 
   
Total  
per Capita 
Cost of 
Opioid Crisis  
(b)  
Non-Mortality  
per Capita  
Cost of 
Opioid  
Crisis 
(c) 
Value  
($)  State  
% 
([b/a]*100)  
% 
([c/a]*100) State 
11,958.18  Washington D.C.  30.58  4.12 Washington D.C. 
9,600.38  New Hampshire  37.91  3.75 New Hampshire 
9,473.23  West Virginia  46.21  3.78 Connecticut 
8,722.34  Ohio  38.81  3.79 Washington 
8,612.21  Maryland  38.75  3.72 New York 
 
The spatial variations in the opioid crisis and per capita cost of care in the United States 
can be attributed to geography and socioeconomic factors (Keyes et al., 2014; Ghertner & 
Groves, 2018; Karamouzian & Kerr, 2018). (1) Rural-urban geographic divide – where as noted 
above, rural areas including most of the Appalachian region, parts of the West and the Midwest, 
and New England, are disproportionately more affected by the opioid crisis compared to more 
urban areas; (2) socioeconomic factors – specifically high unemployment and high poverty have 
been shown to be associated with the opioid crisis (Ghertner & Groves, 2018). However, there 
are exceptions to these observed association in which urban areas experience and some 
economically disadvantaged areas do not experience the opioid crisis (Ghertner & Groves, 
2018). These geographic and socioeconomic factors attributable to the opioid crisis have resulted 
in varying; (1) Opioid prescribing and dispensing practices in the United States in which more 
opioids are prescribed and dispensed in the Appalachian region, Southern, and Western states of 
the United States (McDonald et al., 2012). (2) Internal migration patterns in which there is 
movement of people between and within states and counties in search of economic prosperity 
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and better healthcare services (Finkelstein et al., 2018). Furthermore, counties within states in the 
Appalachian region, Southern, and Western United States tend to have more opioids prescribed 
and dispensed. This is due to those counties having greater (i) resident population size (ii) white 
non-Hispanic or African American (iii) economically disadvantaged, uninsured (iv) urban 
classified dwelling population and (v) number of opioid prescribing providers (Wennberg, 2011; 
McDonald et al., 2012; McDonald & Carlson, 2014). In addition, other factors such as political 
affiliations, higher healthcare utilization, greater income disparities, and lower educational 
attainment predispose these counties to prescribing and dispensing more opioids (Webster et al., 
2009; Goodwin et al., 2018; Guy et al., 2017). 
Opioid crisis and provider experience of care 
The quantity of opioid analgesics prescribed grew from 76 million prescriptions in 1990 
to 116 million in 1999 to 255 million in 2012 and declined to 191 million in 2017 – the lowest in 
over 10 years (Baker, 2017, Centers for Disease Control and Prevention, 2018b). However, in 
spite of the overall rate of opioid analgesics prescribing rate in United States climaxing and 
leveling off from 2010 to 2012 and decreasing since 2012, the quantity of opioids in morphine 
milligram equivalents (MME) prescribed per person is still estimated at three times higher than it 
was in 1999 (Centers for Disease Control and Prevention, 2017). This may have contributed in 
part to the rising overall opioid-related deaths in the nation. Such that between 1999 and 2017, 
approximately 218,000 deaths were reported in United States due to overdoses connected to 
prescription opioids – a fivefold increase from 1999 to 2017 (WONDER, 2016).  In addition, in 
1999 and 2017, age-adjusted prescription opioid overdose mortality rates were 4,030 and 40,051 
per 100,000 population respectively. This represents an estimated 10-fold increase is deaths due 
to prescription opioids between 1999 and 2017 (Kaiser Family Foundation, 2018). Furthermore, 
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in 2017, 46 deaths/day were attributed to prescription opioid overdoses accounting for over 35% 
of all deaths related to opioid overdoses in that year (Scholl et al., 2018; Centers for Disease 
Control and Prevention, 2018a). 
Annual prescribing rates between 2006 and 2017 declined by over 19% with most of the 
decline occurring from 2012 to 2017. In addition, prescribing rates of high-dose opioids has been 
reducing since 2008 (Centers for Disease Control and Prevention, 2018a). All indicative of 
cautious prescribing practices on the part of healthcare providers. However, not all healthcare 
provider experiences of caring for individuals with opioid use disorder and opioid related drug 
overdoses during the opioid crisis can be explained by adherence to best prescribing practices 
only. 
The experiences of healthcare providers caring for patients during the opioid crisis may 
be influenced by certain factors. These include: (1) General overutilization of healthcare services 
by individuals with substance use disorders (Walley et al., 2011; National Drug Intelligence 
Center, 2011; Neighbors et al., 2013). (2) Repeated presentations at emergency departments and 
readmissions to hospital of patients with opioid use disorder related conditions and opioid related 
drug overdoses (Walley et al., 2011; National Drug Intelligence Center, 2011; Neighbors et al., 
2013). (3) Disproportionately high costs of healthcare incurred by patients with substance use 
disorders including opioids (Walley et al., 2011; National Drug Intelligence Center, 2011; 
Neighbors et al., 2013). (4) Underutilization or lack of use of substance use disorder-specific 
interventions during inpatient admissions and at discharge (Knudsen et al., 2011; Knudsen & 
Roman, 2012; Rosenthal et al., 2016; Donroe et al., 2016; McCarty et al., 2018).  
Other plausible reasons related to the aforementioned include: (Ia) Associated regulations 
and other treatment policies of patients with opioid use disorder related conditions and opioid 
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related drug overdoses such as certification to dispense opioid drugs in the treatment of OUD 
(CFR Title 42: Part 8: Subparts A through C). (Ib) Policies influencing opioid prescribing 
practices (National Academies of Sciences, Engineering, and Medicine, 2017). (Ic) Additional 
provider requirement to report pain and OUD data (National Academies of Sciences, 
Engineering, and Medicine, 2017). (IIa) Healthcare provider biases such as fears related to 
deception and manipulation by patients with opioid use disorder when presenting with or 
reporting pain. (IIIa) Challenges associated to using agonist and antagonist medication such as, 
patients and families explicitly requesting nondrug treatment, persistently expecting abstinence 
as only appropriate outcome of treatment, resistance of healthcare staff to use of medications, 
and medication cost. (IIIb) Lack of providers capable of prescribing required medications on 
staff in many addiction treatment centers (Knudsen et al., 2011). (IV) Barriers related to routine 
usage of extended-release naltrexone such as, difficulty ordering and administering the 
medication, policies of health plans demanding prior authorization and review of utilization, 
requirements of first failing at use of other treatment options, need for patients being free of 
opioids the prior 7 to 10 days before injection, lack of care continuity by physicians, and cultures 
that are resistant use of medication (Alanis-Hirsch et al., 2016). 
All of these factors may result in healthcare provider dissatisfaction and burnout, which 
adversely affects their experience of caring for patients with opioid use disorder related 
conditions, and opioid related drug overdoses. This may ultimately lead to poor patient 
experience of care including dissatisfaction and poor quality of care, poor population health 
outcomes, and increased per capita cost of care (Bodenheimer & Sinsky, 2014). 
Why is Opioid Use Disorder (OUD) important?   
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Opioids – The estimated cost of the opioid crisis the United States between 2001 and 
2017 exceeded $1.0 trillion and is projected to rise to $1.5 trillion by 2020 (Altarum, 2018). 
Evidence shows that prescription opioids, not heroin, are the first opioids frequently abused 
(Cicero et al, 2014). Approximately 67% of primary heroin users also use prescription opioids 
(Rosenblum et al, 2007). Use of heroin and heroin-related mortality in the United States have 
been on the rise since 2000 (Rudd et al, 2016). 
Opioid Use Disorder (OUD) – OUD is a chronic relapsing condition involving frequent 
misuse of prescription opioids, diversion and use of opioids, or use of heroin acquired illegally. 
OUD is usually associated with considerably high rates of morbidity and mortality (Strain et al, 
2015). Opioid use disorder, according to the DSM-V combines two disorders, namely; Opioid 
Dependence and Opioid Abuse. OUD encompasses use of a wide range of illegal and prescribed 
drugs of the opioid class (Hartney & Gans, 2018; Regier et al, 2013). Adverse events – such as 
overdosing, abuse, dependence, and death – from using prescription opioids in the United States 
have risen over the last 20 years (Chang et al, 2018). Opioid abusers have greater odds of visiting 
the emergency departments, physician outpatient clinics; longer inpatient stays compared to non-
abusers of opioids (Meyer et al, 2014). 
Identifying individuals with OUD particularly in the ED can be challenging. This is 
partly because there are no existing clinical guidelines for such tasks (Duber et al., 2018). 
Clinically, individuals with OUD may present to the ED with somatic symptoms and signs such 
as headaches and pain involving the joints, back, neck, chest or abdomen, elevated heart rate and 
blood pressure; and psychological symptoms like agitation, panic attacks, and restlessness 
(Braden et al., 2010; Kampman & Jarvis, 2015; Duber et al., 2018). Several different tools have 
been developed for identifying patients or individuals with OUD (Duber et al., 2018). The 
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similarities between these tools are that they accurately and reliably identify patients with OUD 
while being easy to administer and integrate into providers’ existing workflows (Johnson et al., 
2013; Duber et al., 2018). 
Prevalence of opioid use disorder 
Approximately 12 million individuals 12 years and older misused prescription opioids in 
the United States in 2016 (Reinhart et al, 2018). Over 130 people are estimated to die per day 
from opioid-related overdoses (Centers for Disease Control and Prevention/National Center for 
Health Statistics, 2018). According to the National Survey on Drug Use and Health, an estimated 
total of 7.7 million, 7.4 million, and 7.6 million people 12 years and older suffered from OUD in 
the 12 months preceding the survey in 2015, 2016, and 2017 respectively (SAMHSA – Center 
for Behavioral Health Statistics and Quality, 2017, 2018). In addition, results from the National 
Survey on Drug Use and Health revealed that in the 12 months prior to the survey, 2.1 million 
people 12 years and older were first time misusers of prescription opioids. (SAMHSA – Center 
for Behavioral Health Statistics and Quality, 2018). In 2015 or the most recent year, there was 
significant state-level variability in OUD diagnosed in healthcare settings; aggregated data 
revealed an estimated 10-fold difference in diagnosed OUD prevalence between South Dakota 
(least impacted state at 1.32 per 1,000) and Vermont (most impacted state at 12.56 per 1,000) 
(Davenport & Matthews, 2018). 
Economic burden of opioid use disorder 
Prescription abuse costs society $55 billion each year, with $20 billion in emergency 
department and inpatient care alone (Fuehrlein et al, 2017). Approximately 75% treatment costs 
for alcohol & other drug use disorder (DUD) including OUD is publicly funded alone (Mark et 
al, 2005). Treatment expenditure for substance use disorder including OUD in the United States 
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increased from $9 billion in 1986 to $21 billion in 2003 to $24 billion in 2009 and $31 billion in 
2014 (Mark et al., 2007; SAMHSA, 2013b; SAMHSA, 2014). This amount is projected to 
increase to about $42 billion in 2020 (SAMHSA, 2014). 
Importance of opioid use disorder prevalence and cost in adolescents and young adults 
Significant increases in opioid prescribing across all age groups have been observed in 
recent years with parents more likely to share opioids with their children and/or diversion of 
parents’ opioid pain relievers by children thus predisposing to OUD (Binswanger & Glanz, 
2015). The most commonly initiated drugs of abuse among children, adolescents, and young 
adults are opioids (SAMHSA, 2010). Adolescents (12-17 year old) and young adults (18-25 year 
old) presenting to primary care with OUD and overdoses has been on the rise in the last 15 years 
(Saloner et al., 2017). Misuse and abuse of prescription opioids in individuals 12-17 years old 
and 18-25 years old more than doubled between 1991 and 2012 (SAMHSA, 1993, 2013a). An 
estimated 5.4% of 12-17 year olds and 10% of 18-25 year olds reported nonmedical use of 
prescription opioids (Binswanger & Glanz, 2015). In addition, 16.1% of 12-17 year olds and 
20.9% of 18-25 year olds were at-risk of initiation of heroin use in the past year following prior 
nonmedical opioid pain reliever use between 2002 and 2011 (Muhuri et al., 2013). The 
proportion of admissions into substance abuse treatment facilities due to opioid use in 
individuals 12 years and older increased from 18% in 2004 to 30% in 2014 (SAMHSA, 2014, 
2017). There has been a six-fold increase of unintentional opioid poisonings in youth in the last 
10 years (Binswanger & Glanz, 2015). In spite of expanded access to medications, on average 
only 11.1% of 13 to 17 year olds received Buprenorphine and Naltrexone for OUD between 
2001 and 2014 (Hadland et al., 2017). Disparities based on age, gender, and race/ethnicity exist 
for OUD treatment among 13 to 25 year olds (Hadland et al., 2017; Feder et al., 2017). In 
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addition, other characteristics such as; census region, insurance status, annual income, patient 
location, hospital designation/location, treatment setting (e.g. ED, inpatient, and outpatient), and 
disposition have been shown to influence prevalence and cost of OUD treatment (Wu et al., 
2016; Peterson et al., 2018; Hadland et al., 2017; Mosher et al., 2017; Gaither et al., 2016; Xie et 
al., 2014). Specifically, studies using the Nationwide Emergency Department Sample (NEDS) 
have used the following: (1) individual variables – age, gender, primary payer, annual median 
income, patient location; and (2) hospital variables – control/ownership, region, designation; and 
type of emergency department event (disposition) including treated & released, admitted to same 
hospital, transferred to another or died (Chandwani et al., 2013; Mejia et al., 2018; Upadhyay et 
al., 2018; Rivera et al., 2017; Singh et al., 2016; Wall et al., 2015; Wang et al., 2015). In 2013, 
only 0.4% of 15-17 year olds compared to 12.0% of 18 year olds and older with prescription 
OUD; and only 2.4% of 15-17 year olds compared to 26.3% of 18 year olds and older with 
heroin use disorder received medication-assisted treatment (MAT) (Feder et al., 2017). 
Importance of emergency departments in opioid use disorder 
Emergency departments (EDs) are engaged in managing the untoward consequences of 
inappropriately prescribed opioids (Xie et al, 2014; Duber et al., 2018; Salzman et al., 2020). 
About 305,900 ED visits were related to the nonmedical use of opioids in 2008, a 111% increase 
from the 144,600 ED visits in 2004 (Xie et al, 2014). 
State-level opioid policies 
State lawmakers in the United States are engaging different sectors such as health, 
criminal justice, human services, and so on to create innovative policies aimed addressing the 
current opioid crisis deemed as a public health emergency (U.S HHS, 2017). These efforts are 
going on in addition to ensuring appropriate and needed access to pain management. A minimum 
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of 33 states had enacted legislation related to opioid prescription limits as of October l, 2018 
(Blackman, 2017). 
As of July 1 2017, in United States, 49 States, District of Columbia, and St. Louis County 
in Missouri have operational Prescription Drug Monitoring Programs (PDMPs) that have 
capacity to receive and distribute controlled substance prescription information to authorized 
users (National Alliance for Model State Drug Laws, 2017). 
As of 2019, in United States, 49 States and the District of Columbia with exception of  
Wyoming have operational Opioid Treatment Programs (OTP) that provide medication-assisted 
treatment (MAT) – use of medications with counseling and behavioral therapies to provide 
holistic treatment – for individuals diagnosed with opioid use disorder (OUD) and to prevent 
opioid overdose (Kaiser Family Foundation, 2019; SAMHSA, 2015, 2019). 
In spite of state-level opioid policies, there are still geographic variations to the opioid 
crisis. In addition to causes of the geographic variations in opioid crisis and per capita cost of 
care stated above, other factors may be responsible for observed state-level variations in opioid 
usage in United States. These include (Martin et al., 2016): (1) Availability of, access to, scope 
of regulation, and use of Prescription Drug Monitoring Programs (PDMPs). (2) Attitudes of the 
population regarding pain and opioid-containing substances. (3) Attitudes of law enforcement 
towards individuals using opioids and incarceration of such individuals. (4) Judicial enforcement 
using drug courts or mandating treatment versus imprisonment. (5) Addiction treatment 
availability and referrals to these facilities and other treatment resources. (6) Addiction treatment 
reimbursement. (7) Reimbursement of insurance for screening and analysis of risk. (8) Heroin 
and other illicitly produced synthetic opioids availability in the community. (9) Healthcare 
providers and patients education. (10) Oversight of patients taking and providers prescribing 
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controlled substances. (11) Community resources and involvement in response to opioid crisis. 
(12) Probable effects of genetic variations or cultural influences on specific populations. 
Therefore, to address convincingly the opioid crisis, an understanding of the specific 
features of the opioid crisis in individual states and geographic regions is necessary in addition to 
policies. 
Policy/intervention evaluation 
Effect of policies on prescribing practices – Following a uniform rise in overall national 
rate of opioid prescribing beginning in 2006, the total quantity of opioid prescriptions written 
and dispensed reached a climax in 2012 at approximately 255.2 million prescriptions equivalent 
to a prescribing rate of 81.3 prescriptions per 100 persons (Centers for Disease Control and 
Prevention, 2018b). Thereafter, from 2012 to 2017, overall national prescribing rates of opioids 
analgesics decreased. This decline in overall national opioid analgesic prescribing rate reached 
its ebb in 2017, the lowest in over 10 years for an estimated total of 191.2 million prescriptions 
equivalent to a prescribing rate per 100 persons of 58.7 prescriptions (Bao et al., 2016, 2018; 
Centers for Disease Control and Prevention, 2018b; Bohnert et al., 2018;). Policies related to use 
of state prescription drug monitoring programs (PDMPs) particularly comprehensive legislative 
mandates to use PDMPs and laws allowing healthcare providers who prescribe opioids to 
delegate use of PDMPs to their office staff have been more effective compared to laws 
compelling state participation in interstate sharing of PDMP data at reducing opioid prescribing 
rates (Bao et al., 2018). 
In 2017, however, certain areas across the United States still witnessed very high opioid 
prescribing rates perhaps due in part to consistently higher quantity of opioids in morphine 
milligram equivalents (MME) prescribed per person, causes of geographic variations, and other 
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factors discussed earlier. For instance, some United States counties had prescribing rates per 100 
persons that were seven times higher than the national average of 58.7. In addition, opioid 
analgesics prescriptions still being dispensed in 16% of counties in United States were enough 
for everyone in the nation to have one (Centers for Disease Control and Prevention, 2018b). 
Thus, it is reasonable to conclude that though policies limiting supply of prescription and other 
sources of legal opioids are necessary, they are not sufficient to address the opioid crisis.  
Effect of policies on opioid overdoses – The prescribing rate of opioid analgesics had 
declined annually since 2012 reaching a 10-year low in 2017 (Centers for Disease Control and 
Prevention, 2018b). However, national and state-level opioid overdose deaths continued to rise 
within the same period from 2012 to 2017 (Kaiser Family Foundation, 2017a; National Institute 
on Drug Abuse, 2018a). Plausible reasons for this may be as discussed earlier, persistently higher 
MMEs of opioids still prescribed per person, clusters of counties around the country still 
prescribing opioids over five times that of the national average, and high dispensing rate of 
opioid analgesics by almost 20% of counties nationwide (Centers for Disease Control and 
Prevention, 2018b). In addition to over-prescription in some parts of the country, it is not 
possible to rule out diversion and misuse of prescription opioids. Furthermore, prescription 
opioids even when prescribing rates have declined are still precursors to addiction and 
transitioning to illegal opioids and a reason for rising opioid overdose mortalities (Compton & 
Wargo, 2018). The above reasons were supported in a systematic review by Fink and colleagues 
in 2018, which revealed that the impact of implementing PDMPs on opioid overdoses was 
equivocal because there were evidences that implementing PDMPs was associated with 
declining or rising nonfatal or fatal opioid overdoses (Fink et al, 2018).     
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Effect of policy on opioid use disorder – Medication-assisted treatment (MAT) is 
effective for treating opioid use disorder (OUD). Use of MAT leads to: (1) increased social 
functioning and retention in treatment program of affected individuals; (2) reduced, use of 
opioids, overdosing on opioids, criminal activities, risky behaviors promoting transmission of 
HIV and hepatitis C virus (HCV), morbidity and mortality (Mattick et al., 2009, 2014; Schwartz 
et al., 2013; SAMHSA, 2015; Connery, 2015; US HHS, 2016).  
Medications used in MAT include, buprenorphine (Suboxone®, Subutex®), methadone, and 
extended release naltrexone (Vivitrol®), with buprenorphine and methadone considered essential 
medicines (WHO, 2004; National Institute on Drug Abuse, 2018a, 2016). However, these 
medications are not extensively used and where they are used; access to the medications is a 
major issue (Jones et al., 2018). The nationwide percentage of admissions for opioid treatment 
with treatment plans including receipt of medications such as MAT decreased from 35.2% in 
2002 to 27.6% in 2013 before increasing to 36.9% in 2015 then decreasing again to 33.5% in 
2016. This trend was occurring while total opioid admissions increased between 2002 and 2016. 
(SAMHSA, 2014, 2017, 2018). This fluctuating trend may have been due to initially insufficient 
treatment capacity (responsible for the 2002-2013 decline) (Jones et al, 2015; Jones et al., 2018) 
which progressively improved and/or availability of multiple treatment options in U.S. States 
(responsible for the 2013-2015 rise and 2015-2016 decline) (Jones et al., 2018). 
Overall, the impact of MAT on OUD has been equivocal (Kampman & Jarvis, 2015; 
Potter et al., 2015; Weiss et al., 2015). Medication assisted treatment (MAT) has proven 
effectiveness in treating OUD following initiation of MAT in an estimated 50% of patients with 
prescription OUD at 18 months (Potter et al., 2015) and 61% of patients with prescription OUD 
at 42 months (Weiss et al., 2015). Conversely, it has proven to be ineffective in approximately 
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50% and 39% of patients with prescription OUD at 18 and 42 months follow-up post-initiation 
of MAT respectively (Potter et al., 2015; Weiss et al., 2015). 
Selected state-level comparison of the opioid crisis 
The states of Texas, New York, and Kentucky are selected to highlight the variation in 
statistics of the opioid crisis in the United States.  
Texas – Is located in southern United States. Specifically, in the West South Central division 
where the overall burden of the opioid epidemic is light. There are very few available facilities 
located in Texas, which, provide some but not all three forms of MAT. The state of Texas has 
not expanded Medicaid (SAMHSA, 2017; National Institute on Drug Abuse, 2018b; Jones et al., 
2018). 
New York – Is located in the northeast United States. Specifically, in the Middle Atlantic 
division where the overall burden of the opioid epidemic is relatively heavy. There are many 
facilities located in New York providing all three forms of MAT. These facilities are clustered 
together. The state of New York has expanded Medicaid (SAMHSA, 2017; National Institute on 
Drug Abuse, 2018b; Jones et al., 2018).  
Kentucky – Is located in the southern United State. Specifically, in the East South Central 
division where the overall burden of the opioid epidemic is heavy. There are very few available 
facilities located in Kentucky, which provide some but not all three forms of MAT. The state of 
Kentucky has expanded Medicaid. (SAMHSA, 2017; National Institute on Drug Abuse, 2018b; 
Jones et al., 2018).  
In 2016, Texas had an opioid-related overdose death rate of 4.9 deaths per 100,000 persons. 
However, the number of heroin and synthetic opioids death rates has steadily increased since 
2010. New York State had an opioid-related overdose death rate of 15.1 deaths per 100,000 
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persons in the same year. The heroin-related and synthetic opioids deaths were over two times 
and ten times more since 2012. Similarly, in Kentucky with an opioid-related overdose death rate 
of 23.6 deaths per 100,000 persons, the heroin-related deaths more than doubled and synthetic 
opioids deaths were over six times more since 2012.  
A comparative analysis of the opioid crisis by the numbers between Texas, New York, and 
Kentucky is shown below. 
Table 2. Comparative Analysis of Opioid Crisis between the States of Texas, New York, and 
Kentucky 
Characteristics 
States 
National Average 
Texas New York Kentucky 
Opioid pain reliever 
prescriptions (opioid 
prescriptions per 100 
persons) (2016) 
57.6 42.7 97.2 70.6 
Total number of 
prescriptions (millions) 
(2016) 
15.44 9.53 4.18 214.88 
Opioid related overdose 
deaths (2016) 
1,375 1,641 989 42,000 
Opioid related overdose 
death rates (deaths per 
100,000 persons) (2016) 
4.9 15.1 23.6 13.3 
Total per capita cost of 
opioid crisis ($ per 
resident) (2015) 
653 1,850 2,412 --- 
Non-mortality per capita 
cost of opioid crisis ($ per 
resident) (2015) 
144 320 205 --- 
Total healthcare 
expenditure per capita by 
state of residence ($) 
(2015) 
7,006.31 9,789.61 8,013.50 8,054.55 
Sources: (Kaiser Family Foundation, 2017b; National Institute on Drug Abuse, 2018b; Centers 
for Disease Control and Prevention, 2018b). 
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Public Health Significance 
The opioid crisis in America appears to be worsening. State-level policies legitimizing 
interventions such as use of Prescription Drug Monitoring Programs (PDMPs) that have capacity 
to receive and distribute controlled substance prescription information and Opioid Treatment 
Programs (OTP) that provide medication-assisted treatment (MAT) for opioid use disorder 
(OUD) and to prevent opioid overdose have made modest impacts on prescribing practices, 
opioid overdoses, and opioid use disorder. These interventions though promising have 
challenges, which need to be adequately addressed if they are to make significant positive 
impacts on the opioid crisis.   
This research will provide most current prevalence of diagnosing and treating OUD in 
12-18 year olds and those over 18 with OUD based on their ED disposition. In addition, this 
research will use a robust sample of nationally representative data including those 12 years of 
age and older. Furthermore, it will provide accurate estimates to guide policy and program 
implementation regarding management of opioid use disorder in the emergency department. 
Specific Aims 
The specific aims of this research are: 
Aim 1:  
To systematically identify, appraise, and collect state-by-state level data on status of medication-
assisted treatment (MAT) policies, MAT medication coverage status for OUD treatment, 
Medicaid expansion status, and Medicaid section 1115 behavioral health waiver status for OUD 
treatment in all 50 states and the District of Columbia captured in the literature. 
Aim 2: 
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To examine individual characteristics (Primary payer, Annual median income, Patient location, 
and Type of emergency department event), hospital characteristics (Control/Ownership, Region, 
and Designation), and state-level policy characteristics (MAT policy status, MAT medication 
coverage status for treating OUD, Medicaid expansion status, and Medicaid section 1115 
behavioral health waiver status for OUD treatment) associated with prevalence of emergency 
department diagnosis and treatment of any opioid use disorder (OUD) in U.S. population 12 
years and older from January 2016 to December 2016 captured in the Nationwide Emergency 
Department Sample (NEDS) database.  
Conceptual Research Model 
Research Models Referenced in the Literature 
General Model of State Policy Adoption (Miller, 2005) – The general model of state 
policy adoption posits that the determinants of adoption of policy arise from both a state’s 
external and internal environment. External factors include policy adoptions by other states and 
federal assistance, law and regulation. Internal factors comprise the economic and political 
circumstances of a particular state in addition to baseline program and policy characteristics. 
Socioeconomic factors directly influence Medicaid program and other policy attributes; and 
indirectly influence Medicaid program and other policy attributes by first influencing political 
system development, which, in turn, produces policy outputs that feedback into the 
socioeconomic and/or political environment. 
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Source: https://www.sciencedirect.com/science/article/pii/S0277953605002376 
Structure, Process and Outcomes Framework by Avedis Donabedian – Avedis 
Donabedian described a widely adopted and adapted framework for assessing, investigating, and 
understanding quality of care using the structure, process and outcomes constructs (Donabedian, 
1966; Donabedian, 2005).  
Donabedian’s reasoning was that the definition of outcomes and types of measures 
selected for measurement of outcomes were both imperative for understanding quality in health 
care. In addition, in his landmark article Donabedian described the significant role process-
related factors played in understanding and evaluating quality. He noted that rooted in the 
processes of care are values, standards and normative judgments that drive performance of 
patient care activities to improve patient health. Furthermore, Donabedian also highlighted the 
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important influence of structure of care or physical and organizational context such as personnel, 
equipment, facilities, financial and operational processes and so on that support healthcare on 
quality (Donabedian, 1966; McDonald et al., 2007). 
Donabedian’s structure-process-outcomes framework is flexible and allows for different 
interpretations and applications in different circumstances (Donabedian, 1966; Donabedian, 
2005). 
 
Source: https://www.ncbi.nlm.nih.gov/books/NBK44008/figure/A25995/?report=objectonly   
Research Model 
 The model for this study combined Donabedian’s structure-process-outcomes framework 
and the General Model of State Policy Adoption. In this study, Donabedian’s framework was 
embedded within the General Model of State Policy Adoption. The relationships between both 
models and the study aims are depicted thus: 
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STRUCTURE OUTCOMES PROCESS 
Patient Characteristics: 
Insurance status, Annual 
median income, Patient 
location   
Hospital Characteristics: 
Control/Ownership, Region, 
Designation 
State Policy Characteristics: 
MAT policy status, MAT 
medication coverage status, 
Medicaid expansion status, 
Medicaid section 1115 
behavioral health waiver status 
  
 
 
ED Event: 
Treated & released, 
Admitted to same 
hospital, 
Transferred, Died 
Prevalence Aim 2 
State-Level Opioid Policies: Aim 1 
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METHODS 
Study Design 
 This research involved a retrospective secondary data analysis of the Nationwide 
Emergency Department Sample (NEDS) from January 1, 2016 to December 31, 2016. 
Data Sources 
 Nationwide Emergency Department Sample (NEDS) – The NEDS is the largest all-payer 
emergency department (ED) database in the United States, yielding national estimates of 
hospital-based ED visits. NEDS was developed for the Healthcare Cost and Utilization Project 
(HCUP) and is maintained by the Agency for Healthcare Research and Quality (AHRQ). NEDS 
produces regional and national estimates about hospital-owned emergency department (ED) 
visits across the United States. The NEDS describes ED visits, regardless of whether they result 
in admission. Information includes geographic characteristics, hospital characteristics, patient 
characteristics, and the nature of visits (e.g., common diagnoses for ED visits). The NEDS was 
constructed using the Healthcare Cost and Utilization Project (HCUP) State Emergency 
Department Databases (SEDD) and the State Inpatient Databases (SID). HCUP data inform 
decision-making at the national, state, and community levels. The SEDD capture discharge 
information on ED visits that do not result in an admission (i.e., treat-and-release visits, transfers 
to another hospital, and deaths). The SID contain information on patients initially seen in the ED 
and then admitted to the same hospital.  
The 2016 NEDS includes a full calendar year of data with diagnosis and procedure codes 
reported using the International Classification of Diseases, Tenth Revision, Clinical 
Modification/Procedure Coding System ICD-10-CM/PCS). 
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 American Society of Addiction Medicine (ASAM) state reports (American Society of 
Addiction Medicine et al., 2013); Substance Abuse and Mental Health Services Administration 
(SAMHSA) Office of Policy, Planning and Innovation State Medicaid coverage reports 
(Substance Abuse and Mental Health Services Administration et al., 2014, 2018); and Kaiser 
Family Foundation (KFF) report on the opioid epidemic (Kaiser Family Foundation, 2018b, 
2019a, 2019b) – for nationwide state level medication-assisted treatment (MAT) policy, MAT 
medication coverage status, Medicaid expansion status, and Medicaid section 1115 behavioral 
health waiver status data. These data provided the state-by-state summary of medication-assisted 
treatment (MAT) policy status, Medicaid coverage status of the MAT medications for treating 
OUD, Medicaid expansion status, and Medicaid section 1115 behavioral health waiver status 
used in this study. 
Study Population 
Target Universe  
Emergency departments (ED) in community, nonrehabilitation U.S. hospital-owned ED 
that reported total ED visits in the American Hospital Association (AHA) Annual Survey 
Database. Equivalent to 144,842,742 ED events in 2016. 
Exclusion criterion – non-rural hospitals that reported less than ten ED visits in a year. 
Sampling Frame   
Hospital-owned ED in the 35 States and the District of Columbia that provided 
information on ED visits that result and do not result in admission. The sampling frame of the 
NEDS was limited to a subset of the universe: hospital-owned ED in the States and District of 
Columbia for which Healthcare Cost and Utilization Project (HCUP) ED data (SID and SEDD) 
were available. The list of hospital-owned ED in the sampling frame consisted of all AHA 
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community, nonrehabilitation hospitals that reported total ED visits in each of the sampling 
frame States and District of Columbia that could be matched to the ED data provided to HCUP. 
If an ED in the AHA survey could not be matched to the ED data provided by the HCUP data 
source, it was eliminated from the sampling frame (but not from the target universe). The HCUP 
hospitals were required to be represented in the AHA data and have no more than 90 percent of 
their ED visits resulting in admission. Equivalent to 113,306,272 ED events in 2016. 
Exclusion criterion – HCUP hospitals that were not represented in the AHA data and had more 
than 90 percent of their ED visits resulting in admission.  
Sample Size Calculation and/or Study Power 
Sample size  
The 2016 NEDS is a 20% stratified probability sample of target universe drawn from the 
sampling frame based on five hospital-based stratification variables including, United States 
Census region, trauma center designation, urban-rural hospital location, ownership, and teaching 
status. It therefore represented the diversity of hospitals across the United States. A sample size 
of 20 percent was based on previous experience with similar research databases. A larger sample 
would be cumbersome for data users, given that a 20 percent sample contains about 30 million 
records. A 20 percent sample also enables the user to split the NEDS into two 10 percent 
subsamples for estimation and validation of models. Therefore, the 2016 NEDS contained 
32,680,232 ED visits in 953 hospitals across 35 states and the District of Columbia. Post-
stratification discharge weights defined by the Healthcare Cost and Utilization Project (HCUP) 
were used to calculate national estimates. The use of these weights enabled each HCUP database 
discharge entry to be adjusted to estimate values from specific portions of the overall United 
States population. The number of ED visits weighted for national estimates was 144,842,742. In 
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2016, the national rate of opioid-related ED visits per 100,000 population was 243.5 with a range 
of 223 to 268. 
The HCUP states in the 2016 NEDS included; Arizona, Arkansas, California, Connecticut, 
District of Columbia, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, 
Maine, Maryland, Massachusetts, Minnesota, Mississippi, Missouri, Montana, Nebraska, 
Nevada, New Jersey, New York, North Carolina, North Dakota, Ohio, Oregon, Rhode Island, 
South Carolina, South Dakota, Tennessee, Utah, Vermont, Wisconsin, and Wyoming. 
Figure of HCUP States and the District of Columbia included in the 2016 NEDS. 
 
Source: https://www.hcup-us.ahrq.gov/db/nation/neds/NEDS_Introduction_2016.jsp#ta1 
Note: The above graphic outlines states in the NEDS by Region. In the Western region, AZ, CA, 
HI, MT, NV, OR, UT, WY were in the HCUP NEDS. The following states were not in the 
NEDS in this region - AK, CO, ID, NM, WA. In the Midwestern region, IA, IN, IL, KS, MN, 
MO, ND, NE, OH, SD, WI were in the HCUP NEDS. The following state was not in the NEDS 
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in this region - MI. In the Northeastern region, CT, MA, ME, NJ, NY, RI, VT were in the HCUP 
NEDS. The following states were not in the NEDS in this region - NH, PA. In the Southern 
region, AR, DC, FL, GA, KY, MD, MS, NC, SC, TN, TX were in the HCUP NEDS. The 
following states were not in the NEDS in this region - AL, DE, LA, OK, VA, WV. 
 Cases of opioid use disorder (OUD) were identified using International Classification of 
Disease, Tenth Revision, Clinical Modification (ICD-10-CM) codes. These cases were assessed 
for characteristics associated with prevalence including, (1) Patient (Primary payer, Annual 
median income, Patient location, and Type of emergency department event – treated & released, 
admitted to same hospital, transferred to another or died). (2) Hospital (Control/Ownership, 
Region, and Designation).  
The American Psychiatric Association Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5) Classification recommended ICD-10-CM codes for opioid use 
disorder (OUD) beginning October 1, 2017 are F11.1*for opioid abuse and F11.2* for opioid 
dependence. The code for uncomplicated opioid abuse is F11.10, which is applicable to mild 
OUD. The code for uncomplicated opioid dependence is F11.20 which is applicable to moderate 
and severe OUD (ICD-10-CM Diagnosis Code, 2018; American Psychiatric Association, 2013). 
Study Power 
For the systematic review, following good research practice, a convenience sample size 
of the 35 states and the District of Columbia which contributed to the 2016 NEDS database was 
used in this study. 
For the secondary analysis of the 2016 NEDS cross-sectional dataset of this study, the 
minimal required sample size was calculated based on a power of 80% and a significance level 
(α) of 0.05. 
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To calculate the sample size required for this survey study, the follow were needed 
(Abramson, 2008; Selwyn, 2011): 
“p” – A reasonably close estimate of estimate of the actual prevalence – if in 
doubt, 50% was used; this maximized the sample size and, hence, erred on the safe side. 
“d” – The maximum acceptable difference between the estimated prevalence 
(based on the sample) and the actual prevalence; this “acceptable margin of error” was 
half the confidence interval. 
“t” – The required confidence interval – usually 95% 
Also, the size of the population; its effect on the calculated sample size – the 
Finite Population Correction (f.p.c) was small, unless the population was very 
small. 
Initial sample size (n) calculation; 
Using the formula, n = (t2pq)/d2 
Where n=sample size; t=Z of 95% confidence=1.96; p=prevalence estimate=50%; 
q=1-p=50%; d=absolute error or sampling error=10%. 
n = (1.962*0.5*0.5)/0.12 = 96.04 = 97 
Sample size calculation corrected for Finite Population Correction (f.p.c); 
Based on good sampling practice, sample was ≥10% of the sample size of 32,680,232 ED 
visits. In this research, 2016 NEDS was 20% of probability sample of target universe 
drawn from the sampling frame. 
Using the sample size of emergency departments (ED) in community, nonrehabilitation U.S. 
hospital-owned EDs that reported total ED visits in the American Hospital Association (AHA) 
Annual Survey Database, N = 32,680,232 
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Initial sample size, n = 97 
Thus, sampling fraction = n/N = 97/144,842,742 = 6.7*10-7 x100% = 6.7*10-5% 
Therefore, since the sampling fraction was very low, the f.p.c was close to unity and the 
correction had a negligible influence and was omitted (Armitage et al., 2002). 
Sample size calculation corrected for nonresponse (NR); 
 Based on good sampling practice, an NR of 10% was expected. 
Therefore, the new sample size, n1 = n/(1-NR) = 97/(1-0.1) = 107.8 = 108. 
Based on a sample size of 108, calculated power using STATA version 15.0 = 55%. But based 
on good sampling practice, a power of at least 80% was expected which amounted to a 
calculated sample size of 194. However, 2016 NEDS sample size was 32,680,232 which 
provided adequate size to detect any significant difference. 
Data Collection and Management 
Discharge-level administrative NEDS data was collected based on efforts of hospitals in 
participating states that maintain statewide data systems. Unweighted ED visit data were 
collected on actual visits, then weighted proportionately to total number of ED visits in the 
country based on the sampling strategy. The NEDS is a stratified single-stage cluster sample of 
state-level ED data reported to healthcare cost and utilization project (HCUP). 
All emergency department (ED) discharge-level data totaling 32,680,232 ED visits in 953 
hospitals across 35 states and the District of Columbia contributing to and collected in the 2016 
NEDS were used in this study. This dataset provided the largest repository of individual level 
discharge data from all ED visits nationwide capable of providing patient and hospital 
characteristics associated with prevalence of diagnosing and treating OUD in U.S. Emergency 
Departments. 
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Data security and confidentiality – Data in the 2016 NEDS database were recoded to 
ensure ease of analysis. Missing data were excluded from the final dataset for analysis. 
Data location and management – Final dataset for analysis was password protected and 
study materials secured in a locked cabinet. 
Quality Control 
The following quality control procedures were used to assess data quality and perform 
basic editing for the NEDS: 
Quality control editing procedures – Data editing was performed using the following 
explicit rules. (a) Made the data usable without extensive further editing. (b) Confirmed that data 
values were valid, internally consistent, and consistent with established norms, when feasible. (c) 
Used some edit procedures to set questionable and inconsistent values to inconsistent (.C or 
negative 6-filled). Used other edit procedures only to tabulate edit failures. Used the latter to 
evaluate whether systematic problems exist. (d) Never "fix" or imputed data. Set invalid or 
inconsistent values to special missing values. This preserved the analyst's ability to investigate 
data anomalies. (e) Some data elements were coded more reliably because they related to 
reimbursement. For example, diagnoses, procedures, age, sex, and discharge disposition were 
part of the algorithm to assign Diagnosis Related Group (DRG) on an inpatient record. (f) 
Tabulated instances of edit failures and used these to assess data quality for each data source. 
Quality review procedure – An independent contractor reviewed the following statistics 
for the 2016 NEDS. (a) Means, number of missing and non-missing values, minimum, and 
maximum for all numeric data elements. (b) Mean, median, and extreme values for continuous 
variables such as length of stay and charges. (c) Frequency distributions for all categorical and 
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some continuous data elements. (d) Cross frequencies for closely related data elements (e.g., 
point of origin compared to admission type).  
Automated quality review control procedures – Each discharge record was subjected to 
the following procedures. (a) To assess validity of values – For numeric data: Verifying numeric 
data as numeric. Checking the range against legal values documented by the data source. 
Checking the range against standard norms (e.g., length of stay is a non-negative value; age in 
years is between 0 and 124, the maximum allowed by the DRG grouper). Checking the values 
against the maximum allowed for the data element (e.g., birth weight less than 20 pounds). For 
character data: Verifying against norms, when feasible (e.g., diagnosis codes and procedure 
codes). (b) To assess internal consistency – Comparing values of related data elements (e.g., a 
procedure of hysterectomy should appear with a sex of female; admission date should occur 
before discharge date). If an inconsistency involved a critical data element (such as discharge 
date and admission date), as much information as reasonable was retained. For example, If 
discharge date fell before admission date, discharge date was retained and admission date and 
length of stay set to inconsistent (.C or negative 6-filled). If discharge date was invalid (e.g., 
February 30), discharge quarter and discharge year were retained. (c) To assess consistency with 
established norms – Comparing values to an established norm (e.g., maternal diagnoses should 
occur with an age between 10 and 55 years). 
Measures 
Individual patient encounters resulting in a diagnosis of any opioid-related incidents 
including the diagnosis of OUD were identified in NEDS using ICD-10-CM diagnostic codes. 
According to the DSM-5 classification of the American Psychiatric Association, beginning 
October 1, 2017, ICD-10-CM codes for OUD are F11.1* for opioid abuse and F11.2* for opioid 
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dependence (WHO, 1992, 1993). This study used F11.10, the code for uncomplicated opioid 
abuse which was applicable to mild OUD and F11.20, the code for uncomplicated opioid 
dependence which was applicable to moderate and severe OUD (ICD-10-CM Diagnosis Code, 
2018; American Psychiatric Association, 2013). A composite variable “OUD_Condition” based 
on whether the individual patient encounter resulted in a diagnosis and treatment of OUD, 
specifically uncomplicated opioid abuse or uncomplicated opioid dependence was created. 
Depending on the presence of opioid abuse or opioid dependence, “OUD_Condition was then 
recoded as ‘0’ – Uncomplicated opioid abuse; and ‘1’ – Uncomplicated opioid dependence. 
These cases of OUD were assessed for factors associated with prevalence (patient demographic – 
Primary payer, Annual median income, Patient location, and Type of emergency department 
event – treated & released, admitted to same hospital, transferred to another or died; hospital – 
Control/Ownership, Region, and Designation; and state-level policy – MAT policy status, MAT 
medication coverage status, Medicaid expansion status, and Medicaid section 1115 behavioral 
health waiver status).  
The cohort of cases in this study were patients 12 years and older. Children from 12 years 
were included in this study because there has been significant increases in opioid prescribing 
across all age groups observed in recent years (Binswanger & Glanz, 2015). In addition, opioids 
have become the most commonly initiated drugs of abuse among youth. There has been a six-
fold increase of unintentional opioid poisonings in youth in the last 10 years. Furthermore, 5.4% 
of 12-17 year olds and 10% of 18-25 year olds reported nonmedical use of prescription opioids 
in 2012 (Binswanger & Glanz, 2015). Therefore, treatment plans that are effective, practical, and 
scalable are needed for the young population with OUD (Borodovsky et al, 2018). 
Variables 
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Outcome variables: The outcome variables for this study included: (i) State-level opioid 
policy – which was defined as the type of state-by-state opioid policy in existence. Specifically, 
state-level opioid policy were characterized by, (a) MAT policy status – presence or not of state-
level MAT policy. (b) MAT medication coverage status – coverage of all three MAT 
medications used for OUD treatment (comprehensive coverage) or coverage of two or less of 
MAT medication used for OUD treatment (non-comprehensive coverage) (Grogan et al, 2016; 
Blanchard et al, 2018). (c) Medicaid expansion status – number of states that have adopted and 
not adopted Medicaid expansion. (d) Medicaid section 1115 behavioral health waiver status – 
number of states that have approved and not approved for behavioral health exclusion waivers 
for OUD treatment. (ii) Prevalence – which was defined as the proportion of cases of opioid use 
disorder (OUD) diagnosed and treated in the Emergency Department (ED) within a 12-month 
period from January 2016 to December 2016.  
Predictor variables: The predictor variables in this study were grouped into two 
categories. (1) Primary predictor variable – (i) Opioid use disorder (OUD) condition – which was 
defined as the presence of a diagnosis of uncomplicated opioid abuse and uncomplicated opioid 
dependence during an individual patient encounter at the ED within a 12-month period from 
January 2016 to December 2016. (2) Covariates – (i) Patient characteristics – primary payer, 
annual median income, patient location and ED event. (ii) Hospital characteristics – 
control/ownership, region, and designation. (iii) State-level policy characteristics – MAT policy 
status, MAT medication coverage status, Medicaid expansion status, and Medicaid section 1115 
behavioral health waiver status.  
Measurement Matrix 
 
Outcome Variables 
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Variable 
category 
Variable Definition Source Related  
Aim 
Type 
State-Level 
Opioid Policy 
Opioid Policy 
Characteristics of state-
level opioid policy 
(including: MAT policy 
status – not present=0, 
present=1; MAT 
medication status – non-
comprehensive=0, 
comprehensive=1; 
Medicaid expansion status 
– not adopted=0, 
adopted=1, and Medicaid 
section 1115 behavioral 
health waiver status – not 
approved=0, approved=1) 
American 
Society of 
Addiction 
Medicine 
(ASAM) State 
Report, 
Substance 
Abuse and 
Mental Health 
Services 
Administration 
(SAMHSA),   
and Kaiser 
Family 
Foundation 
(KFF) Report 
 
 
Aim 1 
 
Systematic review 
of state-by-state 
opioid policies 
Prevalence Prevalence 
The proportion of cases of 
opioid use disorder (OUD) 
diagnosed and treated for 
in the Emergency 
Department  (ED) within a 
12-month period from 
January 2016 to December 
2016 
 
Nationwide 
Emergency 
Department     
Sample 
(NEDS) 
 
 
Aim 2 
 
 
Continuous 
Predictor variables 
Variable 
category 
Variable Definition Source Related  
Aim 
Type 
Primary 
OUD Diagnosis OUD_Condition Presence of a diagnosis of 
opioid abuse or 
dependence during an 
individual patient 
encounter at the ED within 
a 12-month period from 
January 2016 to December 
2016. (including, 0= 
diagnosed opioid abuse , 
1= diagnosed opioid 
dependence) 
Composite 
derived from 
Nationwide 
Emergency 
Department     
Sample 
(NEDS) 
Aim 2  
 
Categorical 
(Binary) 
Covariates 
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Patient 
Characteristics 
Primary payer 
Expected primary payer of 
ED services (including, 
1=Medicare, 2=Medicaid, 
3=Private including HMO, 
4=Self-pay, 5=No charge, 
6=Other) 
 
NEDS 
 
Aim 2  
 
 
Categorical 
(Nominal) 
Annual Median 
Income 
National quartile of 
median household income 
estimated using patient's 
residential zip code 
(include, 1=$1-$42,999, 
2=$43,000-$53,999, 
3=$54,000-$70,999, and 
4=≥$71,000) 
 
NEDS 
 
Aim 2  
 
 
Categorical 
(Ordinal) 
 Patient location 
Urban-rural designation  
of patient’s county of  
residence (include, 1=large 
central metropolitan, 
2=large fringe 
metropolitan, 3=medium 
metropolitan, and 4=small 
metropolitan, 
5=micropolitan, 6=not 
metropolitan or 
micropolitan) 
 
 
NEDS 
 
 
Aim 2  
 
 
 
Categorical 
(Nominal) 
 ED Event 
Type of patient ED event 
(include, 1=treated & 
released, 2=admitted to 
same hospital, 
3=transferred to another 
hospital, 9=died) 
 
NEDS 
 
Aim 2 
 
Categorical 
(Nominal) 
Hospital 
Characteristics 
Control/Owners
hip 
Ownership status of 
ED/hospital (include, 
0=all, 
1=public[government, 
non-Federal, 
2=voluntary[private, not-
for-profit], 
3=proprietary[private, 
investor-owned/for-profit], 
4=private[private 
voluntary/proprietary]) 
 
 
Nationwide 
Emergency 
Department     
Sample 
(NEDS) 
 
 
Aim 2  
 
 
 
Categorical 
(Nominal) 
Region 
Region of the U.S.  
hospital is located 
(include, 1=Northeast, 
 
NEDS 
 
Aim 2  
 
 
Categorical 
(Nominal) 
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2=Midwest, 3=South, and 
4=West) 
Designation 
Hospital urban-rural 
designation (include, 
1=large metropolitan area, 
2=small metropolitan area, 
3=Micropolitan area, and 
4=Non-urban residual) 
 
NEDS 
 
Aim 2  
 
 
Categorical 
(Nominal) 
State-Policy 
Characteristics 
MAT Policy 
Status 
Presence or absence of 
MAT policy. (including, 
0=Not present, 1=Present) 
ASAM State 
Report, 
SAMHSA,   
and KFF 
Report 
Aims 1& 2 Categorical 
(Binary) 
MAT 
Medication 
Coverage 
Status 
Presence or absence of 
MAT medication 
coverage status. 
(including, 0= non-
comprehensive 
coverage, 1=has 
comprehensive 
coverage) 
ASAM State 
Report, 
SAMHSA,   
and KFF 
Report 
Aims 1& 2 
Categorical 
(Binary) 
Medicaid 
Expansion 
Status 
Adoption or not 
Medicaid expansion. 
(including, 0= not 
adopted, 1=Adopted) 
KFF Report Aims 1& 2 
Categorical 
(Binary) 
Medicaid 
Section 1115 
Behavioral 
Health Waiver 
Status 
Section 1115 behavioral 
health waiver status. 
(including, 0=not 
approved, 1=Approved) 
KFF Report Aims 1& 2 
Categorical 
(Binary) 
 
Data Analysis 
Overview 
 The final dataset for analysis was organized, recoded and analyzed manually by research 
staff.  
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Descriptive statistics including frequency and proportions were used to analyze the final data 
collected. In addition to hierarchical linear regression model (HLM) was used to analyze the 
final data collected.  
Data analysis was performed using Statistical Package for Social Sciences (SPSS) version 25.0 
developed by IBM Corporation. 
Secondary analyses 
Aim 1: To systematically identify, appraise, and collect state-by-state level data on status of 
medication-assisted treatment (MAT) policies, MAT medication coverage status for OUD 
treatment, Medicaid expansion status, and Medicaid section 1115 behavioral health waiver status 
for OUD treatment in all 50 states and the District of Columbia captured in the literature. 
 Methods – Review of the identified data sources – American Society of Addiction 
Medicine (ASAM) state reports; Substance Abuse and Mental Health Services Administration 
(SAMHSA) Office of Policy, Planning and Innovation State Medicaid coverage reports; and 
Kaiser Family Foundation reports on the opioid epidemic was performed to identify, appraise 
and collect relevant data on nationwide state-level opioid policy status, MAT medication 
coverage status for treating OUD, Medicaid expansion status, and Medicaid section 1115 
behavioral health waiver status for OUD treatment. While, the aim of the review which was to 
identify, appraise, and collect state-level opioid policies in all 50 states and the District of 
Columbia in the United States captured in the literature was accomplished, only policies 
specifically within the 35 states of the US and the District of Columbia contribution to the 2016 
NEDS were used in the analysis. These included; Arizona, Arkansas, California, Connecticut, 
District of Columbia, Florida, Georgia, Hawaii, Iowa, Illinois, Indiana, Kansas, Kentucky, 
Maine, Maryland, Massachusetts, Minnesota, Missouri, Mississippi, Montana, North Carolina, 
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North Dakota, Nebraska, New Jersey, Nevada, New York, Ohio, Oregon, Rhode Island, South 
Carolina, South Dakota, Tennessee, Utah, Vermont, Wisconsin, and Wyoming. The University 
of Texas Health Science Center at Houston Committee for the Protection of Human Subjects – 
also known as Institutional Review Board (IRB) – approval was not required for this process as 
no human subjects were needed. 
Results – Findings from each of the 50 States opioid policy evaluated for specific criteria 
including MAT policy status, MAT medication coverage status for treating OUD, Medicaid 
expansion status and Medicaid section 1115 behavioral health waiver status was presented Table 
2 shown below. 
Aim 2: To examine individual or patient characteristics (Primary payer, Annual median income, 
Patient location and Type of emergency department event), hospital characteristics 
(Control/Ownership, Region, and Designation), and state-level policy characteristics (Opioid 
policy status, MAT medication coverage status for treating OUD, Medicaid expansion status, 
and Medicaid section 1115 behavioral health waiver status for OUD treatment) associated with 
prevalence of emergency department diagnosis and treatment of any opioid use disorder (OUD) 
in U.S. population 12 years and older from January 2016 to December 2016 captured in the 
Nationwide Emergency Department Sample (NEDS) database. 
 Method – Data preparation: Core dataset – For this study, this dataset was also known as 
the patient-level dataset. Only the variables of interest were retained in the core (patient-level) 
dataset. These included, “DX_OUD” – the ICD-10-CM Diagnosis for OUD; “PAY1” – the 
primary expected payer (uniform), “ZIPINC_QRTL” – the median household income national 
quartile for patient zip code, “PL_NCHS” – the patient location: NCHS urban-rural code, and 
“EDEVENT” – the type of ED event. A new variable “nDX_OUD” was created to represent the 
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string to numeric recode of OUD diagnosis variable “DX_OUD”. Using ICD-10-CM codes, the 
diagnoses of any opioid-related incident in the ED were identified from the patient-level dataset. 
The identification of occurrence of any opioid-related was classified using ICD-10-CM codes 
into: (1) opioid abuse, (2) adverse effects of opioids, (3) opioid dependence and unspecified use, 
and (4) opioid poisoning. This approach of using ICD codes to categorize any opioid-related 
incident has been documented and used in previous studies (More & Barrett, 2017; Vivolo-
Kantor et al., 2018; Litaker et al., 2019; Geller et al., 2019; Salzman et al., 2020). Subsequently, 
the ICD-10-CM Diagnosis for uncomplicated opioid abuse was recoded as “0” and the ICD-10-
CM Diagnosis for uncomplicated opioid dependence was recoded as “1”.  
Hospital dataset – only the variables of interest were retained in the hospital dataset. These 
included, “HOSP_CONTROL” – the control/ownership of hospital, “HOSP_REGION” – the 
region of hospital, “HOSP_URCAT4” – the hospital urban-rural designation, and 
“TOTAL_EDVisits” – the total number of ED visits from this hospital in the NEDS. A new 
variable “PREV_RXOUD_ED” was derived to represent the prevalence of diagnosing and 
treating OUD in ED at the hospital level. To determine the prevalence of diagnosing and treating 
OUD in the ED at the hospital level, it was assumed that: (1) patients were diagnosed and treated 
for OUD at least during one ED visit; (2) the total ED visits – “TOTAL_EDVisits” – for each 
hospital represented the total number of times each patient was treated at least once for OUD. 
Therefore, the prevalence of diagnosing and treating OUD in the ED at the hospital level 
(“PREV_RXOUD_ED”) was calculated by dividing each TOTAL_EDVisits per hospital by the 
total number of ED visits for all hospitals for the duration of the study under consideration, 
which was 32,680,232 emergency department (ED) visits. In other words, PREV_RXOUD_ED 
= TOTAL_EDVisits per hospital/Sum of TOTAL_EDVisits (Woltman et al., 2012). 
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“HOSP_ED” – the HCUP ED hospital identifier and “DISCWT” – the weight to ED visits in 
AHA universe for each of the cases in the core and hospital datasets were also retained.  
The hospital dataset was then merged with the core (patient-level) dataset in a one-to-many 
merger using HOSP_ED, the unique identifier common to both the core (patient-level) and 
hospital datasets.   
State-level policy dataset – the state-level policy dataset was created by abstracting the required 
data from the identified sources. Four variables were identified and categorized as “MAT_POL” 
– representing the MAT policy status which was coded as “0” when not present and “1” when 
present, “MAT_COV” – representing MAT medication coverage status which was coded as “0” 
for “No” when not comprehensive and as “1” for “Yes” when comprehensive, “MED_EXP” – 
representing Medicaid expansion status which was coded as “0” for “No” when not adopted and 
“1” for “Yes” when adopted, and “MED_1115” – representing Medicaid section 1115 behavioral 
health waiver status which was coded as “0” for “No” when not approved and “Yes” when 
approved.  
As part of the data preparation requirements for the statistical analysis, the patient-, and hospital-
level datasets were merged into a single dataset file and the cases in the final dataset file sorted in 
ascending order – that is, from lowest to highest value – using HOSP_ED, the unique identifier 
common to all individual data files.  
Pearson’s chi-squared test was used following cross-tabulation of “nDX_OUD” by the patient 
and hospital characteristics to determine if the differences between the diagnosis of opioid abuse 
and opioid dependence were statistically significant. Pearson’s chi-squared test was also used 
after cross-tabulation of “HOSP_REGION” by the patient and hospital characteristics to 
determine if the differences between the regions were statistically significant. 
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Statistical analysis – Hierarchical linear models (HLM) (Huta, 2014; Anderson, 2012; Woltman 
et al., 2012; Aiken, et al., 2018) were used to estimate the association between the outcome 
variable (prevalence) and predictor variables (patient demographic –primary payer, annual 
median income, patient location and type of emergency department event – treated & released, 
admitted to same hospital, transferred to another or died; and hospital – control/ownership, 
region, and designation). HLM was used as the inferential statistical analysis method of choice 
for this study because: (1) there were two levels of units in the dataset for this study, i) patients – 
were level 1 units because of multiple individual per hospital, and ii) hospitals – were level 2 
units because there were multiple hospitals per state in the dataset. As such, the final dataset used 
for analysis in this study consisted of 2-level hierarchies. (2) The unweighted sample sizes of the 
levels in the hierarchy differed from patient-level (174,061) to hospital-level (953). (3) There 
were missing values at the patient-level, the lowest level of the hierarchy, which HLM can 
handle. (4) There were no missing data at the hospital-level of the hierarchy thus HLM was more 
suitable as there was no need for imputing missing data at this levels before performing HLM 
regression. (5) The cases or records at the patient-level were indistinguishable [HLM can be 
utilized when cases are distinguishable or not] (Huta, 2014; Anderson, 2012; Woltman et al., 
2012).  
Tests of Normality – The outcome variable, PREV_RXOUD_ED, was tested to determine if it 
was normally distributed (See Appendix A - Tests of Normality Results). It was not normally 
distributed. Therefore, PREV_RXOUD_ED was log transformed to “PREV_RXOUD_ED_Log” 
and re-tested for the normality assumption (See Appendix A - Tests of Normality Results). It was 
relatively more normally distributed. Additionally, the tests of HLM assumptions using 
PREV_RXOUD_ED and PREV_RXOUD_ED_Log revealed more violations of these 
 
                                                                                                                           60 
 
assumptions with PREV_RXOUD_ED than PREV_RXOUD_ED_Log (See Appendix C - HLM 
Regression and Test of Assumptions Results). Thus, it was determined to proceed with the HLM 
regression analysis using the transformed outcome variable, PREV_RXOUD_ED_Log. 
Furthermore, the relationship between outcome variable, PREV_RXOUD_ED_Log and all the 
predictor variables was assessed for linearity and was found to be linear. 
Missing Data – Little’s Missing Completely at Random (MCAR) Test was performed on the 
transformed outcome and predictor variables in the dataset to determine the proportion of 
missing data for each variable and how to handle the missing data (See Appendix B - MVA) 
(Little & Schenker, 1995). There were no missing data in the transformed outcome variable – 
Prevalence (“PREV_RXOUD_ED_Log”). The predictor variables were all categorical as such; 
expectation maximization (EM) statistics were not computed. Only patient-level variables – 
specifically PAY1, ZIPINC_QRTL, PL_NCHS – had missing data to the proportions of 0.1%, 
3.1%, and 1.7% respectively (See Appendix B - MVA). Given the large sample size of this 
study, the missing data were not replaced (Allison, 2001; Dong & Peng, 2013).  
Test of HLM Assumptions – HLM assumptions were tested for the purposes of this study and no 
major violations of these assumptions were found (See Appendix C). Specifically, error or 
residual structure and predictor variables assumptions were tested. For this study, error structure 
assumptions tested for included ensuring that: patient-level (Level 1) residuals were independent 
and normally distributed; hospital-level (Level-2) random effects were independent, multivariate 
and normally distributed; and inter level residuals were independent. Predictor variables 
assumptions tested for in this study included ensuring that: no multicolinearity exist between 
predictor variables and residuals at all levels – that is, patient-level (Level 1) predictor variables 
were independent of patient-level residuals and hospital-level (Level-2) predictor variables were 
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independent of hospital-level residuals respectively and the predictor variables at the patient-, 
and hospital-levels were independent of the random effects at the other levels (Huta, 2014; 
Anderson, 2012; Woltman et al., 2012). The statistical analyses for this study was conducted 
using IBM SPSS Statistics version 25. All tests of hypotheses were two-tailed with a type-1 error 
rate set at 5%. 
Human Subjects, Animal Subjects, or Safety Considerations  
 This study used data from the 2016 Nationwide Emergency Department Sample (NEDS). 
The 2016 NEDS is publicly available data developed for the Healthcare Cost and Utilization 
Project (HCUP). The HCUP was developed through a Federal-State-Industry partnership 
sponsored by the Agency for Healthcare Research and Quality. HCUP data inform decision 
making at the national, state, and community levels. There was no need for submission of a 
public use file data agreement form to access the dataset. The dataset does not contain personal 
identifiers that can be linked back to individual level emergency department visits. The proposal 
for this study was reviewed by the University of Texas Health Science Center, School of Public 
Health Office of Research. The status of this study was determined by the University of Texas 
Health Science Center at Houston Committee for the Protection of Human Subjects to be 
exempt. The researcher of this study completed human subject ethics training through the 
Collaborative Institutional Training Initiative prior to the commencement of the project. 
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RESULTS 
A total of 32,680,232 ED visits to 953 hospitals across 35 states and the District of 
Columbia which when generalized to the entire United States in 2016 amounted to 144,842,742 
visits to the ED in 4,639 hospitals across the 50 states including the District of Columbia were 
analyzed in this study. Of these weighted ED visits, 1,623,490 visits were due to opioid-related 
incidents.  
Descriptive Statistics 
The overall prevalence of any opioid-related incident in a U.S. ED observed in the 2016 
NEDS was 1.12%. Figure 1 reveals the proportions of the broad categories of opioid-related 
incidents that were diagnosed and treated for across the ED in the United States in 2016. Almost 
half of these opioid-related incidents were the results of opioid dependence (47.21%). Over 1 in 
5 (21.92%) of the incidents were due to opioid abuse. Opioid poisoning constituted just less than 
20% while just over 10% of the incidents were because of adverse effects of opioids (Figure 1). 
Figure 1. Proportions of the Categories of Any Opioid-Related Incident in U.S. Emergency 
Departments 
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Table 1 details the categories, ICD-10-CM codes, descriptions, frequencies, and 
proportions of all opioid-related incidents observed in 2016. There were 132 ICD-10-CM 
diagnosis codes identified for any opioid-related incident; 119 (90.15%) of these were observed 
in the 2016 NEDS (Table 1). There were preponderant opioid-related incidents diagnosed and 
treated in the U.S. ED in 2016. These included: uncomplicated opioid dependence (26.01%); 
uncomplicated opioid abuse (20.80%). Opioid dependence with withdrawal (11.35%); initial 
encounter with accidental poisoning by heroin (8.37%); initial encounter with adverse effect of 
other opioids (6.67%); unspecified, uncomplicated opioid use (5.52%). Initial encounter with 
adverse effect of unspecified narcotics (3.54%); initial encounter with accidental poisoning by 
other opioids (3.35%). Initial encounter with accidental poisoning by unspecified narcotics 
Opioid Abuse, 
21.92%
Adverse Effects 
of Opioids, 
11.79%Opioid 
Dependence and 
Unspecified Use, 
47.21%
Opioid 
Poisoning, 
19.08%
Proportions of Any Opioid-Related Incident by Category 
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(2.43%); opioid dependence in remission (1.77%); initial encounter with intentional self-harm 
through poisoning by other opioids (1.09%); and initial encounter with adverse effect of 
synthetic narcotics (1.00%) (Table 1) (Figure 2). 
Table 1. Categories, Descriptions, Frequencies, and Proportions of Any Opioid-Related Incident 
Observed in 2016. 
Opioid-Related 
Incident 
Category 
ICD-10-CM 
Code Description 
Frequency 
(N=1,623,490) 
Proportion 
(%) 
Opioid Abuse 
(n=13) 
F1110  Opioid abuse, uncomplicated  337,639 20.80 
F11120  Opioid abuse with intoxication, uncomplicated  2,062 0.13 
F11121  Opioid abuse with intoxication delirium  1,023 0.06 
F11122  
Opioid abuse with intoxication with perceptual 
disturbance  130 0.01 
F11129  Opioid abuse with intoxication, unspecified  8,614 0.53 
F1114  Opioid abuse with opioid-induced mood disorder  1,813 0.11 
F11150  
Opioid abuse with opioid-induced psychotic disorder with 
delusions  
130 0.01 
F11151  
Opioid abuse with opioid-induced psychotic disorder with 
hallucinations  
242 0.01 
F11159  
Opioid abuse with opioid-induced psychotic disorder, 
unspecified  
483 0.03 
F11181  Opioid abuse with opioid-induced sexual dysfunction  0 0.00 
F11182  Opioid abuse with opioid-induced sleep disorder  57 0.00 
F11188  Opioid abuse with other opioid-induced disorder  2,270 0.14 
F1119  Opioid abuse with unspecified opioid-induced disorder  1,447 0.09 
Adverse Effects 
of Opioids  
(n=18) 
T400X5A  Adverse effect of opium, initial encounter  3,282 0.20 
T400X5D  Adverse effect of opium, subsequent encounter  20 0.00 
T400X5S  Adverse effect of opium, sequela  18 0.00 
T402X5A  Adverse effect of other opioids, initial encounter  108,298 6.67 
T402X5D  Adverse effect of other opioids, subsequent encounter  325 0.02 
T402X5S  Adverse effect of other opioids, sequela  229 0.01 
T403X5A  Adverse effect of methadone, initial encounter  2,923 0.18 
T403X5D  Adverse effect of methadone, subsequent encounter  10 0.00 
T403X5S  Adverse effect of methadone, sequela  32 0.00 
T404X5A  Adverse effect of synthetic narcotics, initial encounter  16,243 1.00 
T404X5D  Adverse effect of synthetic narcotic, subsequent encounter  39 0.00 
T404X5S  Adverse effect of synthetic narcotic, sequela  43 0.00 
T40605A  Adverse effect of unspecified narcotics, initial encounter  57,489 3.54 
T40605D  
Adverse effect of unspecified narcotics, subsequent 
encounter  
86 0.01 
T40605S  Adverse effect of unspecified narcotics, sequela  107 0.01 
T40695A  Adverse effect of other narcotics initial encounter  2,215 0.14 
T40695D  Adverse effect of other narcotics, subsequent encounter  14 0.00 
T40695S  Adverse effect of other narcotics, sequela  0 0.00 
Opioid 
Dependence and 
Unspecified Use 
(n=29) 
F1120  Opioid dependence, uncomplicated  422,249 26.01 
F1121 Opioid dependence, in remission 28,727 1.77 
F11220  Opioid dependence with intoxication, uncomplicated  1,214 0.07 
F11221  Opioid dependence with intoxication delirium  1,005 0.06 
F11222  
Opioid dependence with intoxication with perceptual 
disturbance  
171 0.01 
F11229  Opioid dependence with intoxication, unspecified  3,183 0.20 
F1123  Opioid dependence with withdrawal  184,301 11.35 
F1124  Opioid dependence with opioid-induced mood disorder  5,100 0.31 
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F11250  
Opioid dependence with opioid-induced psychotic 
disorder with delusions  
124 0.01 
F11251  
Opioid dependence with opioid-induced psychotic 
disorder with hallucinations  
331 0.02 
F11259  
Opioid dependence with opioid-induced psychotic 
disorder, unspecified  
506 0.03 
F11281  
Opioid dependence with opioid-induced sexual 
dysfunction  0 0.00 
F11282  Opioid dependence with opioid-induced sleep disorder  197 0.01 
F11288  Opioid dependence with other opioid-induced disorder  2,706 0.17 
F1129  
Opioid dependence with unspecified opioid-induced 
disorder  
14,253 0.88 
F1190  Opioid use, unspecified, uncomplicated  89,635 5.52 
F11920  Opioid use, unspecified, with intoxication, uncomplicated  291 0.02 
F11921  Opioid use, unspecified, with intoxication delirium  1,465 0.09 
F11922  
Opioid use, unspecified, with intoxication with perceptual 
disturbance  
42 0.00 
F11929  Opioid use, unspecified, with intoxication, unspecified  908 0.06 
F1193  Opioid use, unspecified with withdrawal  4,037 0.25 
F1194  
Opioid use, unspecified with opioid-induced mood 
disorder  1,197 0.07 
F11950  
Opioid use, unspecified with opioid-induced psychotic 
disorder with delusions  
45 0.00 
F11951  
Opioid use, unspecified with opioid-induced psychotic 
disorder with hallucinations  
234 0.01 
F11959  
Opioid use, unspecified with opioid-induced psychotic 
disorder, unspecified  
364 0.02 
F11981  
Opioid use, unspecified with opioid-induced sexual 
dysfunction  
0 0.00 
F11982  
Opioid use, unspecified with opioid-induced sleep 
disorder  126 0.01 
F11988  
Opioid use, unspecified with other opioid-induced 
disorder  704 0.04 
F1199  
Opioid use, unspecified with unspecified opioid-induced 
disorder  
3,374 0.21 
Opioid 
Poisoning (n=72) 
T400X1A  
Poisoning by opium, accidental (unintentional), initial 
encounter  
2,143 0.13 
T400X1D  
Poisoning by opium, accidental (unintentional), 
subsequent encounter  
5 0.00 
T400X1S  Poisoning by opium, accidental (unintentional), sequela  0 0.00 
T400X2A 
Poisoning by opium, intentional self-harm, initial 
encounter 
252 0.02 
T400X3A Poisoning by opium, assault, initial encounter 6 0.00 
T400X4A  Poisoning by opium, undetermined, initial encounter  274 0.02 
T400X4D  Poisoning by opium, undetermined, subsequent encounter  0 0.00 
T400X4S  Poisoning by opium, undetermined, sequela  0 0.00 
T400X6A Underdosing of opium, initial encounter 174 0.01 
T401X1A  
Poisoning by heroin, accidental (unintentional), initial 
encounter  
135,963 8.37 
T401X1D  
Poisoning by heroin, accidental (unintentional), 
subsequent encounter  
194 0.01 
T401X1S  Poisoning by heroin, accidental (unintentional), sequela  137 0.01 
T401X2A 
Poisoning by heroin, intentional self-harm, initial 
encounter 6,939 0.43 
T401X2D 
Poisoning by heroin, intentional self-harm, subsequent 
encounter 
20 0.00 
T401X2S Poisoning by heroin, intentional self-harm, sequela 17 0.00 
T401X3A Poisoning by heroin, assault, initial encounter 125 0.01 
T401X3S Poisoning by heroin, assault, sequela 4 0.00 
T401X4A  Poisoning by heroin, undetermined, initial encounter  8,877 0.55 
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T401X4D  Poisoning by heroin, undetermined, subsequent encounter  54 0.00 
T401X4S  Poisoning by heroin, undetermined, sequela  19 0.00 
T402X1A  
Poisoning by other opioids, accidental (unintentional), 
initial encounter  
54,432 3.35 
T402X1D  
Poisoning by other opioids, accidental (unintentional), 
subsequent encounter  
61 0.00 
T402X1S  
Poisoning by other opioids, accidental (unintentional), 
sequela  
36 0.00 
T402X2A 
Poisoning by other opioids, intentional self-harm, initial 
encounter 
17,689 1.09 
T402X2D 
Poisoning by other opioids, intentional self-harm, 
subsequent encounter 
38 0.00 
T402X2S Poisoning by other opioids, intentional self-harm 9 0.00 
T402X3A Poisoning by other opioids, assault, initial encounter 96 0.01 
T402X4A  
Poisoning by other opioids, undetermined, initial 
encounter  
4,588 0.28 
T402X4D  
Poisoning by other opioids, undetermined, subsequent 
encounter  
17 0.00 
T402X4S  Poisoning by other opioids, undetermined, sequela  0 0.00 
T402X6A Underdosing of other opioids, initial encounter 1,757 0.11 
T402X6D Underdosing of other opioids, subsequent encounter 9 0.00 
T403X1A  
Poisoning by methadone, accidental (unintentional), 
initial encounter  
7,013 0.43 
T403X1D  
Poisoning by methadone, accidental (unintentional), 
subsequent encounter  
15 0.00 
T403X1S  
Poisoning by methadone, accidental (unintentional), 
sequela  13 0.00 
T403X2A 
Poisoning by methadone, intentional self-harm, initial 
encounter 
1,398 0.09 
T403X2D 
Poisoning by methadone, intentional self-harm, 
subsequent encounter 
8 0.00 
T403X3A Poisoning by methadone, assault, initial encounter 10 0.00 
T403X4A  Poisoning by methadone, undetermined, initial encounter  805 0.05 
T403X4D  
Poisoning by methadone, undetermined, subsequent 
encounter  
5 0.00 
T403X4S  Poisoning by methadone, undetermined, sequela  4 0.00 
T403X6A Underdosing of methadone, initial encounter 274 0.02 
T404X1A  
Poisoning by synthetic narcotics, accidental 
(unintentional), initial encounter  
11,322 0.70 
T404X1D  
Poisoning by synthetic narcotics, accidental 
(unintentional), subsequent encounter  
15 0.00 
T404X1S  
Poisoning by synthetic narcotics, accidental 
(unintentional), sequela  
27 0.00 
T404X2A 
Poisoning by other synthetic narcotics, intentional self-
harm, initial encounter 
5,859 0.36 
T404X2D 
Poisoning by other synthetic narcotics, intentional self-
harm, subsequent encounter 
27 0.00 
T404X3A 
Poisoning by other synthetic narcotics, assault, initial 
encounter 
54 0.00 
T404X4A  
Poisoning by synthetic narcotics, undetermined, initial 
encounter  
791 0.05 
T404X4D  
Poisoning by synthetic narcotics, undetermined, 
subsequent encounter  
0 0.00 
T404X4S  Poisoning by synthetic narcotics, undetermined, sequela  4 0.00 
T404X6A Underdosing of other synthetic narcotics, initial encounter 211 0.01 
T40601A  
Poisoning by unspecified narcotics, accidental 
(unintentional), initial encounter  
39,448 2.43 
T40601D  
Poisoning by unspecified narcotics, accidental 
(unintentional), subsequent encounter  
29 0.00 
 
                                                                                                                           67 
 
T40601S  
Poisoning by unspecified narcotics, accidental 
(unintentional), sequela  
40 0.00 
T40602A 
Poisoning by unspecified narcotics, intentional self-harm, 
initial encounter 
3,677 0.23 
T40602D 
Poisoning by unspecified narcotics, intentional self-harm, 
subsequent encounter 
7 0.00 
T40603A 
Poisoning by unspecified narcotics, assault, initial 
encounter 82 0.01 
T40604A  
Poisoning by unspecified narcotics, undetermined, initial 
encounter  
3,185 0.20 
T40604D  
Poisoning by unspecified narcotics, undetermined, 
subsequent encounter  
8 0.00 
T40604S  
Poisoning by unspecified narcotics, undetermined, 
sequela  
5 0.00 
T40606A Underdosing of unspecified narcotics, initial encounter 85 0.01 
T40691A  
Poisoning by other narcotics, accidental (unintentional), 
initial encounter  
1,105 0.07 
T40691D  
Poisoning by other narcotics, accidental (unintentional), 
subsequent encounter  
0 0.00 
T40691S  
Poisoning by other narcotics, accidental (unintentional), 
sequela  
0 0.00 
T40692A 
Poisoning by other narcotics, intentional self-harm, initial 
encounter 
151 0.01 
T40693A Poisoning by other narcotics, assault, initial encounter 4 0.00 
T40694A  
Poisoning by other narcotics, undetermined, initial 
encounter  
74 0.00 
T40694D  
Poisoning by other narcotics, undetermined, subsequent 
encounter  
0 0.00 
T40694S  Poisoning by other narcotics, undetermined, sequela  0 0.00 
T40696A Underdosing of other narcotics, initial encounter 23 0.00 
T40696S Underdosing of other narcotics, sequela 5 0.00 
Note: Total proportions do not add up to 100% because compared to the absolute values; these 
relative values were rounded up. 
 
Figure 2. Most Preponderant Opioid-Related Incidents in U.S. Emergency Departments 
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Table 2 summarizes state-level opioid policies of all the 50 states of the United States and 
the District of Columbia. Forty-nine states including the District of Columbia (98.0%) had 
medication-assisted treatment policies in place for treating opioid use disorder (OUD). Wyoming 
(2.0%) was the only state that did not have a medication-assisted treatment policy. Forty states 
and the District of Columbia (80.4%) provided comprehensive medication-assisted treatment 
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coverage. Ten states (19.6%) comprising Arkansas, Idaho, Kansas, Kentucky, Louisiana, 
Nebraska, North Dakota, South Carolina, Tennessee and Wyoming did not provide 
comprehensive medication-assisted treatment coverage. Of the 50 states and the District of 
Columbia, thirty-seven (72.6%) had expanded Medicaid. The 14 states (27.4%) that had not 
expanded Medicaid included Alabama, Florida, Georgia, Kansas, Mississippi, Missouri, North 
Carolina, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Wisconsin, and 
Wyoming. In addition, while 31 states (60.8%) had approved Medicaid section 1115 behavioral 
health waiver status, twenty (39.2%) consisting of Alabama, Arkansas, Colorado, Connecticut, 
District of Colombia, Georgia, Idaho, Iowa, Maine, Mississippi, Missouri, Nevada, North 
Dakota, Oklahoma, Oregon, South Carolina, South Dakota, Tennessee, Texas, and Wyoming had 
not approved Medicaid section 1115 behavioral health waiver status (Table 2). 
Table 2. Characteristics of State-Level Opioid Policies for all 50 States and District of Columbia 
State 
Criteria 
MAT Policy status  
MAT 
medication 
coverage status  
Medicaid 
expansion 
status 
Medicaid section 
1115 behavioral 
health waiver 
status 
Alabama* Yes Yes No No 
Alaska* Yes Yes Yes Yes 
Arizona Yes Yes Yes Yes 
Arkansas Yes No Yes No 
California Yes Yes Yes Yes 
Colorado* Yes Yes Yes No 
Connecticut Yes Yes Yes No 
Delaware* Yes Yes Yes Yes 
District of 
Colombia Yes Yes Yes No 
Florida Yes Yes No Yes 
Georgia Yes Yes No No 
Hawaii Yes Yes Yes Yes 
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State 
Criteria 
MAT Policy status  
MAT 
medication 
coverage status  
Medicaid 
expansion 
status 
Medicaid section 
1115 behavioral 
health waiver 
status 
Idaho* Yes No Yes No 
Illinois Yes Yes Yes Yes 
Indiana Yes Yes Yes Yes 
Iowa Yes Yes Yes No 
Kansas Yes No No Yes 
Kentucky Yes No Yes Yes 
Louisiana* Yes No Yes Yes 
Maine Yes Yes Yes No 
Maryland Yes Yes Yes Yes 
Massachusetts Yes Yes Yes Yes 
Michigan* Yes Yes Yes Yes 
Minnesota Yes Yes Yes Yes 
Mississippi  Yes Yes No No 
Missouri Yes Yes No No 
Montana Yes Yes Yes Yes 
Nebraska Yes No Yes Yes 
Nevada Yes Yes Yes No 
New Hampshire* Yes Yes Yes Yes 
New Jersey Yes Yes Yes Yes 
New Mexico* Yes Yes Yes Yes 
New York Yes Yes Yes Yes 
North Carolina Yes Yes No Yes 
North Dakota Yes No Yes No 
Ohio Yes Yes Yes Yes 
Oklahoma* Yes Yes No No 
Oregon Yes Yes Yes No 
Pennsylvania* Yes Yes Yes Yes 
Rhode Island Yes Yes Yes Yes 
South Carolina Yes No No No 
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State 
Criteria 
MAT Policy status  
MAT 
medication 
coverage status  
Medicaid 
expansion 
status 
Medicaid section 
1115 behavioral 
health waiver 
status 
South Dakota Yes Yes No No 
Tennessee Yes No No No 
Texas* Yes Yes No No 
Utah Yes Yes Yes Yes 
Vermont Yes Yes Yes Yes 
Virginia* Yes Yes Yes Yes 
Washington* Yes Yes Yes Yes 
West Virginia* Yes Yes Yes Yes 
Wisconsin Yes Yes No Yes 
Wyoming No No No No 
Note: * = States not participating in 2016 NEDS; MAT policy status as of September 9, 2019 (present 
[Yes]/not present [No]); MAT medication coverage status as of July 1, 2018 (comprehensive [Yes]/non-
comprehensive [No]); Medicaid expansion status as of October 9, 2019 (adopted [Yes]/not adopted [No]); 
Medicaid section 1115 behavioral health waiver status as of October 9, 2019 (approved [Yes], not 
approved [No]).  
Table 3 shows the weighted summary statistics of uncomplicated OUD, patient, hospital, 
and state-level opioid policy characteristics of the 35 states and the District of Columbia that 
contributed to the data analyzed for this study. An estimated 0.5% (759,888/144,842,742) of the 
entire patients who visited the ED in the United States in 2016 were diagnosed with and treated 
for uncomplicated OUD. Of this less than one per cent, more than half of these patients (55.6%) 
were diagnosed with and treated for uncomplicated opioid dependence. The remaining 44.4% 
were diagnosed with and treated for uncomplicated opioid abuse (Table 3). 
The indicators of financial security for the entire patients diagnosed with and treated for 
uncomplicated OUD were largely low with over a third (43.9%) having their treatment paid for 
by Medicaid and slightly less than 1 in 4 (24.8%) were covered by Medicare. Only about 12% of 
the patients paid out-of-pocket. In addition, more than half of these patients earned an annual 
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median income less than $54,000 – just over 1 in 3 (33.8%) earned between $1 and $42,999; and 
less than a quarter earned between $43,000 and $53,999. However, over three-quarters (86.6%) 
of them resided in metropolitan areas (33.3% in large central metropolitan, 23.9% in large fringe 
metropolitan, 21.6% in medium metropolitan, and 7.8% in small metropolitan locations 
respectively). 
Upon visiting the ED, slightly over half (50.8%) of these patients were treated and released; 
47.4% were admitted to the same hospital for further management, and 1.4% were transferred to 
another hospital. Less than one per cent (0.1%) of patients with OUD died in the ED. 
Less than 1 in 5 of the hospital-owned emergency departments visited by the patients diagnosed 
with and treated for OUD were owned by, government (16.6%), private voluntary entities 
(16.3%), private not-for-profit organizations (13.3%), and private for-profit establishments 
(10.0%) respectively. Over two-thirds of these hospital-owned emergency departments were 
located in the southern (35.9%) and midwestern (34.3%) United States respectively. Over 50% 
of these hospital-owned emergency departments were located in metropolitan areas. Specifically, 
27.5% each in large and small metropolitan areas respectively (Table 3).  
Of the 35 states and the District of Columbia analyzed for this study, over three-quarters (77.8%) 
provided comprehensive MAT medication coverage. More than 2 in 3 (69.4%) of the states had 
adopted Medicaid expansion and over half (58.3%) had approved Medicaid section 1115 waiver 
(Table 3). 
Table 3. Summary Statistics of OUD, Patient, Hospital, and State-Level Opioid Policy 
Characteristics 
Variable Category/Variables 
Frequency 
(N=144,842,742) Proportion  
OUD Diagnosis (n=759,888) (%) 
   Opioid abuse 337,639 44.4 
   Opioid dependence 422,249 55.6 
Patient Characteristics   
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Primary Payer:   
   Medicare  187,853 24.8 
   Medicaid 333,228 43.9 
   Private including HMO 118,521 15.6 
   Self-pay 91,999 12.1 
   No charge 4,455 0.6 
   Other 21,993 2.9 
Annual Median Income ($):   
   1-42,999  256,209 33.8 
   43,000-53,999    186,780 24.6 
   54,000-70,999 160,080 21.1 
   ≥71,000 132,315 17.4 
Patient Location:   
   Large central metropolitan 252,420 33.3 
   Large fringe metropolitan 181,384 23.9 
   Medium metropolitan 163,816 21.6 
   Small metropolitan  59,483 7.8 
   Micropolitan 59,506 7.8 
   Not metropolitan or micropolitan 29,327 3.9 
Type of Emergency Department Event:   
   Treated & released  385,157 50.8 
   Admitted to same hospital 359,988 47.4 
   Transferred to another hospital 10,244 1.4 
   Died 897 0.1 
   Other (Not admitted in same hospital & discharged alive) 2,549 0.3 
Hospital Characteristics (n=4,639) (%) 
Control/Ownership:   
   All [government or private] 2,033 43.8 
   Public [government, non-Federal] 770 16.6 
   Voluntary [private, not-for-profit] 617 13.3 
   Proprietary [private, investor-owned/for-profit] 462 10.0 
   Private [private voluntary/proprietary] 758 16.3 
Region:   
   Northeast 535 11.5 
   Midwest  1,590 34.3 
   South 1,665 35.9 
   West 849 18.3 
Designation:   
   Large metropolitan area 1,274 27.5 
   Small metropolitan area 1,274 27.5 
   Micropolitan area 679 14.6 
   Non-urban residual 1,255 27.1 
   Other (Metropolitan [1/2] & Non metropolitan [3/4]) 157 3.4 
State-level Opioid Policy Characteristics (n=36) (%) 
MAT medication coverage status:   
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   Non-comprehensive 8 22.2 
   Comprehensive 28 77.8 
Medicaid expansion status:   
   Not adopted 11 30.6 
   Adopted 25 69.4 
Medicaid section 1115 waiver status:   
   Not approved 15 41.7 
   Approved 21 58.3 
Note: For OUD Diagnosis, Patient Characteristics, and Type of Emergency Department Event, weighted 
n = 759,888. For Hospital Characteristics, weighted n = 4,639. For State-level Opioid Policy 
Characteristics, weighted n = 36 (35 States & D.C.). Overall N=144,842,742. Sum of some variable 
percentages did not attain 100% because missing values were not included. 
 
Table 4 and Figure 3 display the associated state-level opioid policies by hospital region 
of the 35 states and the District of Columbia that contributed to the 2016 NEDS dataset analyzed 
in this study. In the northeast region, there were seven states. All of these States in the 
northeastern region had MAT policies in place and 100% provided comprehensive MAT 
medication coverage. All (100%) of these states had adopted Medicaid expansion while 71.4% 
with the exception of Connecticut and Maine had approved the Medicaid section 1115 
behavioral health waiver. The Midwest region had 11 states, all of which had existing MAT 
policies. However, of these midwestern states, 72.7% excluding Kansas, Nebraska, and North 
Dakota, provided comprehensive MAT medication coverage; 63.6% apart from Kansas, 
Missouri, South Dakota, and Wisconsin had adopted Medicaid expansion; while 63.6% not 
including Iowa, Missouri, North Dakota, and South Dakota had approved the Medicaid section 
1115 behavioral health waiver. The south region comprised 10 states. Of these southern states, 
all (100%) had MAT policies in place, 60% without Arkansas, Kentucky, South Carolina, and 
Tennessee, provided comprehensive MAT medication coverage. While only 40% exclusive of 
Florida, Georgia, Mississippi, North Carolina, South Carolina, and Tennessee had expanded 
Medicaid; and 40% except for Arkansas, Georgia, Mississippi, South Carolina, Tennessee, and 
District of Colombia approved the Medicaid section 1115 behavioral health waiver. Finally, the 
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west region consisted of eight states. In these states, 87.5% with the exception of Wyoming had 
existing MAT policies, provided comprehensive MAT coverage, and had expanded Medicaid 
respectively. The Medicaid section 1115 behavioral health waiver had been approved in 62.5% 
of these western regional states apart from Nevada, Oregon, and Wyoming (Table 4) (Figure 3). 
Table 4. Descriptive Statistics of the 35 State-Level and District of Columbia Opioid Policies by 
Hospital Region 
Hospital 
Region States 
MAT 
Policy 
status 
MAT 
medication 
coverage 
status 
Medicaid 
expansion 
status 
Medicaid section 
1115 behavioral 
health waiver 
status 
Northeast 
(n=7) 
Connecticut  Yes Yes Yes No 
Maine  Yes Yes Yes No 
Massachusetts  Yes Yes Yes Yes 
New Jersey Yes Yes Yes Yes 
New York Yes Yes Yes Yes 
Rhode Island  Yes Yes Yes Yes 
Vermont  Yes Yes Yes Yes 
Midwest 
(n=11) 
Illinois  Yes Yes Yes Yes 
Indiana Yes Yes Yes Yes 
Iowa  Yes Yes Yes No 
Kansas  Yes No No Yes 
Minnesota  Yes Yes Yes Yes 
Missouri  Yes Yes No No 
Nebraska  Yes No Yes Yes 
North Dakota  Yes No Yes No 
Ohio  Yes Yes Yes Yes 
South Dakota Yes Yes No No 
Wisconsin Yes Yes No Yes 
South  
(n=10) 
Arkansas  Yes No Yes No 
District of Colombia  Yes Yes Yes No 
Florida Yes Yes No Yes 
Georgia  Yes Yes No No 
Kentucky Yes No Yes Yes 
Maryland  Yes Yes Yes Yes 
Mississippi  Yes Yes No No 
North Carolina  Yes Yes No Yes 
South Carolina  Yes No No No 
Tennessee  Yes No No No 
West 
(n=8) 
Arizona  Yes Yes Yes Yes 
California  Yes Yes Yes Yes 
Hawaii  Yes Yes Yes Yes 
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Montana  Yes Yes Yes Yes 
Nevada  Yes Yes Yes No 
Oregon  Yes Yes Yes No 
Utah  Yes Yes Yes Yes 
Wyoming  No No No No 
Note: MAT policy status as of September 9, 2019 (present [Yes]/not present [No]); MAT medication 
coverage status as of July 1, 2018 (comprehensive [Yes]/non-comprehensive [No]); Medicaid expansion 
status as of October 9, 2019 (adopted [Yes]/not adopted [No]); Medicaid section 1115 behavioral health 
waiver status as of October 9, 2019 (approved [Yes], not approved [No]). 
 
Figure 3. Overall and Regional Prevalence of State-Level Opioid Policies of the 35 States and 
District of Columbia 
 
Figure 4 represents the overall and regional prevalence of uncomplicated OUD – 
comprised of opioid dependence and opioid abuse – diagnosed and treated in U.S. ED in 2016. 
Overall, over 5 of every 10 patients who presented at a U.S. ED had uncomplicated opioid 
dependence while just over 4 of every 10 patients had uncomplicated opioid abuse. The figure 
however showed noteworthy regional differences. The western region of the U.S. revealed that 
over 6 of every 10 patients seen in the ED in that region was diagnosed and treated for 
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uncomplicated opioid dependence and just over 3 in 10 of the patients had uncomplicated opioid 
abuse. On the other hand, similar to the national average, over 5 of every 10 patients had 
uncomplicated opioid dependence and just over 4 of every 10 patients had uncomplicated opioid 
abuse in southern U.S. However, in northeastern region of the U.S., approximately 5 of every 10 
patients who presented at the ED had uncomplicated opioid dependence or uncomplicated opioid 
abuse. Similarly, in midwestern U.S., about 5 of every 10 patients had either uncomplicated 
opioid dependence or uncomplicated opioid abuse (Figure 4).  
Figure 4. Overall and Regional Prevalence of Uncomplicated OUD Diagnosed and Treated in 
U.S. ED in 2016 
 
In Table 5, overall patient and hospital characteristics between all patients diagnosed with 
and treated for opioid abuse and opioid dependence in the U.S. ED were compared. There were 
significant differences between patients who were diagnosed with and treated for opioid abuse 
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and opioid dependence in the ED in all forms of patient and hospital characteristics (p <0.0001). 
The following patient characteristics depicted these distinct differences more: among patients 
diagnosed with and treated for OUD in the ED, Medicaid paid more for opioid abuse (49.2% vs. 
39.8%) while Medicare paid more for opioid dependence (34.6% vs. 12.4%). In addition, the 
proportion of self-paying (out-of-pocket payment) patients were higher in those diagnosed with 
and treated for opioid abuse (18.2% vs. 7.3%). More patients in the $1-$42,999 annual median 
income bracket were diagnosed with and treated for opioid abuse (36.6% vs. 33.5%). 
Conversely, more patients in the $43,000-$53,999 annual median income bracket were 
diagnosed with and treated for opioid dependence (26.1% vs. 24.6%). There were more patients 
diagnosed with and treated for opioid abuse located in metropolitan areas (89.1% vs. 87.3%). In 
contrast, more patients diagnosed with and treated for opioid dependence were located in 
micropolitan areas (8.5% vs. 7.3%). Concerning the type of ED event that occurred to patients 
when they visited the ED, more patients with opioid abuse were treated and released (64.7% vs. 
39.6%). On the other hand, the proportion of patients diagnosed with and treated for opioid 
dependence who were admitted to the same hospital was more (59.1% vs. 32.8%).  
There was a higher proportion of patients with opioid dependence diagnosed with and treated in 
hospital-owned ED controlled by private not-for-profit entities (10.3% vs. 8.8%) and private 
voluntary organizations (5.0% vs. 3.2%). More patients diagnosed with and treated for opioid 
abuse were seen northeastern (30.7% vs. 25.7%) and midwestern (21.5% vs. 16.7%) United 
States. On the contrary, more of the patient seen in the southern (31.5% vs. 29.8%) and western 
(26.1% vs. 18.0%) regions of the country were diagnosed with and treated for opioid 
dependence. Similarly, the proportion of patients diagnosed with and treated for opioid abuse 
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seen in hospital-owned ED designation as been located in metropolitan areas was more (88.8% 
vs. 87.4%) (Table 5).  
Table 5. Weighted Descriptive Statistics of Patient and Hospital Characteristics Comparing 
Opioid Abuse and Opioid Dependence 
Variable Category/Variables 
Opioid Abuse 
(n=337,639) 
Opioid Dependence 
(n=422,249)  
p value Frequency 
Proportion  
(%) Frequency 
Proportion  
(%) 
Patient Characteristics      
Primary Payer:     <0.0001 
   Medicare  41,777 12.4 146,076 34.6  
   Medicaid 165,389 49.2 167,839 39.8  
   Private including HMO 53,828 16.0 64,693 15.3  
   Self-pay 61,086 18.2 30,913 7.3  
   No charge 2,712 0.8 1,743 0.4  
   Other 11,367 3.4 10,627 2.5  
Annual Median Income ($):      
   1-42,999  118,746 36.6 137,463 33.5  
   43,000-53,999    79,774 24.6 107,006 26.1  
   54,000-70,999 70,251 21.6 89,828 21.9  
   ≥71,000 55,972 17.2 76,342 18.6  
Patient Location:     <0.0001 
   Large central metropolitan 109,662 33.3 142,759 34.3  
   Large fringe metropolitan 84,805 25.7 96,579 23.2  
   Medium metropolitan 73,892 22.4 89,924 21.6  
   Small metropolitan  25,465 7.7 34,018 8.2  
   Micropolitan 24,032 7.3 35,474 8.5  
   Not metropolitan or micropolitan 11,778 3.6 17,550 4.2  
Type of Emergency Department Event:     <0.0001 
   Treated & released  217,928 64.7 167,229 39.6  
   Admitted to same hospital 110,378 32.8 249,610 59.1  
   Transferred to another hospital 6,123 1.8 4,121 1.0  
   Died 676 0.2 221 0.1  
   Other 1,479 0.4 1,069 0.3  
Hospital Characteristics      
Control/Ownership:     <0.0001 
   All [government or private] 272,668 81.0 325,728 77.1  
   Public [government, non-Federal] 8,784 2.6 12,114 2.9  
   Voluntary [private, not-for-profit] 29,656 8.8 43,561 10.3  
   Proprietary [private, investor-
owned/for-profit] 
14,873 4.4 19,685 4.7 
 
   Private [private voluntary/proprietary] 10,604 3.2 21,161 5.0  
Region:     <0.0001 
   Northeast 103,397 30.7 108,457 25.7  
 
                                                                                                                           80 
 
   Midwest  72,449 21.5 70,449 16.7  
   South 100,152 29.8 133,196 31.5  
   West 60,588 18.0 110,147 26.1  
Designation:     <0.0001 
   Large metropolitan area 193,179 57.4 237,509 56.2  
   Small metropolitan area 105,635 31.4 131,767 31.2  
   Micropolitan area 18,553 5.5 28,057 6.6  
   Non-urban residual 5,800 1.7 8,387 2.0  
   Other (Metropolitan [1/2] & Non 
metropolitan [3/4]) 
13,449 4.0 16,531 3.9 
 
Note: For Patient Characteristics, Type of Emergency Department Event and Hospital Characteristics, 
weighted n = 759,888. Overall N=144,842,742. Sum of some variable percentages did not attain 100% 
because missing values were not included.  
 
  Table 6 presents the weighted summary statistics of uncomplicated OUD diagnosis, 
patient and hospital characteristics by hospital region. In all the four hospital regions, there were 
significant differences in patient and hospital characteristics (p <0.0001). Specifically, the 
diagnoses of uncomplicated opioid dependence were more preponderant in the western (64.5%), 
southern (57.1%), and northeastern (52.2%) regions. Uncomplicated opioid abuse was the 
predominant diagnosis in the midwestern region at 50.7%. Patient characteristics that exhibited 
these unique regional differences included: primary payers of diagnosing and treating OUD in 
the ED – where in spite of Medicaid being the predominant payer across all the regions, an 
additional more than 1 in 5 patients were self- (or out-of-pocket) paying in the southern region 
compared to the less than 1 in 10 self-paying patients in the other regions. Annual median 
income revealed that patients in the $1-$53,999 income bracket were mainly in the southern 
(72%), midwestern (57%), and western (54%) regions. The northeastern region comprised 
patients mostly in the $54,000 and higher income bracket (52.5%). Patient location showed that 
over 1 in 10 patients resided in micropolitan areas in the midwestern region compared to other 
regions in addition to the fact that most patients across all regions were overwhelmingly 
metropolitan area dwellers. Over half of the patients presenting to ED in the northeastern and 
midwestern regions respectively were treated and released while about 1 in 2 of the patients seen 
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in ED in the southern and western regions were admitted to the same hospital of the ED to which 
they presented. Regional differences were more pronounced in the following hospital 
characteristics: hospitals’ urban-rural designation revealed that just over 10% of hospitals with 
ED were designated as micropolitan in the midwestern region compared to other regions. This is 
in addition to the overwhelming metropolitan designation of all hospitals across all the regions 
(Table 6). 
Table 6. Weighted Summary Statistics of Opioid Use Disorder Diagnosis, Patient and Hospital 
Characteristics by Hospital Region 
Variable Category/ 
Variables 
Northeast Region 
(n=211,854) 
Midwest Region 
(n=142,898)  
South Region  
(n=233,348) 
West Region 
(n=170,735) 
p value Frequency (%) Frequency (%) Frequency  (%) Frequency (%) 
OUD Diagnosis         <0.0001 
   Opioid abuse 103,397 48.8 72,449 50.7 100,152 42.9 60,588 35.5  
   Opioid dependence 108,457 51.2 70,449 49.3 133,196 57.1 110,147 64.5  
Patient Characteristics          
Primary Payer:         <0.0001 
   Medicare  39,275 18.5 33,597 23.6 62,178 26.7 52,803 31.0  
   Medicaid 117,281 55.4 66,811 46.8 73,498 31.5 75,638 44.4  
 Private including HMO 33,451 15.8 22,568 15.8 35,168 15.1 27,333 16.0  
   Self-pay 15,895 7.5 14,007 9.8 52,247 22.4 9,849 5.8  
   No charge 1,140 0.5 714 0.5 2,490 1.1 111 0.1  
   Other 4,704 2.2 4,956 3.5 7,639 3.3 4,695 2.8  
Annual Median Income ($):          
   1-42,999  59,219 28.8 53,589 38.0 100,793 44.4 42,608 26.3  
   43,000-53,999    38,442 18.7 40,908 29.0 62,582 27.6 44,849 27.7  
   54,000-70,999 51,150 24.9 28,742 20.4 42,668 18.8 37,520 23.2  
   ≥71,000 56,601 27.6 17,877 12.7 20,989 9.2 36,848 22.8  
Patient Location:         <0.0001 
   Large central metropolitan 56,585 27.3 49,281 34.6 65,989 28.6 80,564 48.6  
   Large fringe metropolitan 80,168 38.7 28,183 19.8 58,503 25.4 14,530 8.8  
   Medium metropolitan 45,017 21.7 24,076 16.9 53,234 23.1 41,489 25.0  
   Small metropolitan  11,529 5.6 15,819 11.1 19,072 8.3 13,063 7.9  
   Micropolitan 9,409 4.5 17,954 12.6 19,111 8.3 13,033 7.9  
   Not 
metropolitan/micropolitan 4,334 2.1 7,133 5.0 14,813 6.4 3,047 1.8  
Type of ED Event:         <0.0001 
   Treated & released  117,465 55.4 74,526 52.2 109,366 46.9 83,800 49.1  
   Admitted to same hospital 89,405 42.2 64,813 45.4 120,707 51.7 85,064 49.8  
   Transferred to another 
hospital 3,334 1.6 2,276 1.6 2,920 1.3 1,714 1.0  
   Died 405 0.2 191 0.1 214 0.1 87 0.1  
   Other 1,245 0.6 1,093 0.8 140 0.1 71 0.0  
Hospital Characteristics          
Control/Ownership:         <0.0001 
   All [government or private]   211,854 100.0 124,075 86.8 153,118 65.6 109,349 64.0  
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   Public [government, non-
Federal] 0 0.0 4,194 2.9 11,845 5.1 4,859 2.8  
   Voluntary [private, not-for-
profit] 0 0.0 0 0.0 49,122 21.1 24,096 14.1  
   Proprietary [private, 
investor-owned/for-profit] 0 0.0 0 0.0 19,262 8.3 15,296 9.0  
   Private [private 
voluntary/proprietary] 0 0.0 14,629 10.2 0 0.0 17,136 10.0  
Designation:         <0.0001 
   Large metropolitan area 137,704 65.0 79,320 55.5 131,908 56.5 81,756 47.9  
   Small metropolitan area 58,872 27.8 44,003 30.8 78,568 33.7 55,959 32.8  
   Micropolitan area 8,412 4.0 15,599 10.9 13,693 5.9 8,905 5.2  
   Non-urban residual 3,155 1.5 3,224 2.3 6,166 2.6 1,642 1.0  
   Other (Metropolitan [1/2] & 
Nonmetropolitan [3/4]) 3,711 1.8 752 0.5 3,014 1.3 22,472 13.2  
Note: For Patient Characteristics and Hospital Characteristics, weighted n = 759,888. Sum of some 
variable percentages did not attain 100% because missing values were not included. 
 
Tests of HLM Assumptions Results 
The collinearity statistics revealed no multicollinearity between the predictor variables. 
This is confirmed by the tolerance for each of the predictor variable in models 1 to 2 shown to be 
greater than 1-R2  (i.e. >0.746); and the variance inflation factor (VIF) for each of the predictor 
variable in models 1 to 2 was less than 10 (See Appendix C - Coefficients). In addition, the 
points on the normal probability-probability plot are close to and follow the line (multivariate 
normality); the scatter plot showed relatively scattered dots which were mostly between -3 and 
+3 on both axes indicating that the errors of the data in this study were normally distributed and 
the variance of the residuals were constant (homoscedasticity) (See Appendix C – Normal P-P 
Plot and Scatterplot).  Furthermore, the maximum value of the Cook’s Distance – a measure of 
influential outliers within the predictor variables – was 0.001 (normal <1) which indicated that 
there was no influential value within the predictor variables that could have negatively affected 
models 1 to 2 of the HLM. The minimum and maximum values of the standard residuals were 
expected to be between -3 to +3. In this study, the minimum was -7.446 which was far from -3, 
however, the maximum value was not too far form +3 at +3.900 (See Appendix C – Residual 
Statistics). 
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HLM Regression Results 
In the model 1 of the HLM regression, patient-level characteristics comprising OUD 
diagnosis, primary payer, annual median income, patient location, and type of ED event 
accounted for a significant 15.6% of the variance in prevalence of patients diagnosed with and 
treated for OUD in the ED (R2=0.156, Adjusted R2=0.156, F(5,734621)=27245.686, p<0.0001). 
When the hospital-level characteristics consisting of control/ownership of hospital, region of 
hospital, and hospital urban-rural designation were entered in model 2, they accounted for an 
additional and significant 9.7% of the variance in prevalence of patients diagnosed with and 
treated for OUD in the ED (R2 change=0.097, F(3,734618)=31937.906, p<0.0001). Combined, 
all 8 predictor variables – OUD diagnosis, primary payer, annual median income, patient 
location, type of ED event, control/ownership of hospital, region of hospital, and hospital urban-
rural designation – accounted for a significant 25.4% of the variance in prevalence of patients 
diagnosed with and treated for OUD in the ED (R2=0.254, Adjusted R2=0.254, F change 
(3,734618)=31937.906, p<0.0001). Overall, the patient- and hospital-level predictor variables all 
accounted for a significant proportion of unique variance in the final regression model 
(Appendix C – Model Summary). 
In model 2, the final HLM regression, the ranking of each of the 8 predictor variables 
based on the proportion of the variance accounted for in the prevalence of patients diagnosed 
with and treated for OUD in the ED was reported. These include, control/ownership of hospital 
(9.672%), patient location (6.350%), annual median income (1.440%), hospital designation 
(1.210%), OUD diagnosis (0.202%), primary payer (0.040%), region of hospital (0.025%), ED 
event (0.008%) (Table 7) (Figure 5). 
Table 7. Unstandardized Coefficients, Standardized Coefficients, and Proportion of Variance 
Accounted for by each Predictor Variable in the Hierarchical Linear Models 
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Regression Models/ 
Predictor Variables  B (95%CI) 
Std. Error 
B β p value sr2 
Model 1      
  OUD diagnosis 0.017(0.016,0.019) 0.001 0.026 <0.0001 0.001 
  Primary payer 0.006(0.005,0.007) 0.000 -0.021 <0.0001 0.000 
  Annual median income  -0.028(-0.028,-0.027) 0.000 -0.094 <0.0001 0.010 
  Patient location -0.092(-0.093,-0.092) 0.000 -0.399 <0.0001 0.155 
  ED event 0.000(0.000,0.000) 0.000 -0.006 <0.0001 0.000 
Model 2      
  OUD diagnosis 0.027(0.026, 0.028) 0.001 0.040 <0.0001 0.002 
  Primary payer 0.005(0.004,0.006) 0.000 0.018 <0.0001 0.000 
  Annual median income  -0.031(-0.032,-0.031) 0.000 -0.106 <0.0001 0.014 
  Patient location -0.060(-0.061,-0.060) 0.000 -0.259 <0.0001 0.063 
  ED event 0.000(-0.001,0.000) 0.000 -0.008 0.251 0.000 
  Control/ownership of 
hospital -0.096(-0.096,-0.095) 0.000 -0.320 <0.0001 0.096 
  Region of hospital 0.005(0.004,0.005) 0.000 0.016 <0.0001 0.000 
  Hospital designation -0.023(-0.024,-0.023) 0.000 -0.105 <0.0001 0.012 
Note: B=unstandardized coefficient, CI=confidence interval, β=standardized coefficient 
(indicates the contribution of each predictor variable to the prevalence of treating OUD in the 
ED); sr2=squared semi-partial correlation (indicates proportion of unique variance in prevalence 
of treating OUD in the ED accounted for by each predictor variable). 
 
Figure 5. Ranking of Predictor Variables by their Percentage Influence on Variance of the 
Prevalence of Treating OUD in the ED 
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DISCUSSION 
The overall prevalence of any opioid-related incident diagnosed and treated the U.S. ED 
was 1.12%. This represents a greater than 900% increase in similar visits since 1999 (Salzman et 
al., 2020) and an increase of over 1,000% since 2004 (Xie et al, 2014). Over two-thirds of the 
patients who presented at U.S. ED in 2016 with any opioid-related incident were diagnosed and 
treated for OUD. Specifically, uncomplicated OUD accounted for almost half of these cases. It is 
important however to note that these numbers may have been overestimated since there may 
have been multiple visits to the ED and multiple diagnosis for any given patient. Nevertheless, 
uncomplicated OUD – comprising uncomplicated opioid dependence and uncomplicated opioid 
abuse – was the most prevalent opioid-related incident in 2016 compared to accidental opioid 
poisoning, adverse effect of opioids or intentional opioid poisoning. The implications of this 
finding is that interventions targeted at adequately addressing OUD may potentially reduce the 
burden of the opioid crisis by more than 50%. 
The overall prevalence in this study of ED visits in the entire United States resulting in 
the diagnosis and treatment of uncomplicated OUD was 0.5%. Of these, an estimated fifty-six 
per cent or more than 1 in 2 of the patients who visited the ED had uncomplicated opioid 
dependence. This is in spite of 98% of States in the U.S having functional opioid treatment 
centers, 80.4% of which deliver comprehensive medication-assisted treatment (MAT) with this 
MAT administered in 72.6% of States that have expanded Medicaid and 60.8% that have 
approved Medicaid section 1115 behavioral health waiver (Kaiser Family Foundation, 2019; 
SAMHSA, 2015, 2019). 
Generally, the patients with uncomplicated OUD who visited the hospital-owned ED 
were mostly of low-income status, metropolitan areas residents, covered by Medicaid, and 
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treated and released from the ED. These hospital-owned ED were majorly, controlled by the 
government and privately-owned voluntary organizations, in metropolitan areas, and in the 
Southern and Midwestern United States. Notwithstanding the general characterization of the 
patients with uncomplicated OUD and the hospitals that they presented, there were significant 
patient-, hospital-, and state-policy level differences between uncomplicated opioid dependence 
and uncomplicated opioid abuse. Additionally, significant regional differences were noted for all 
uncomplicated OUD diagnosis and across all categories of patient-, hospital-, and state-level 
policy characteristics.  
From a diagnosis perspective, the patients with uncomplicated opioid dependence were 
preponderantly upper-lower income class, micropolitan residents, covered by Medicare, admitted 
to the same hospital as ED to which they presented; and attended to largely in hospital-owned 
ED that were privately-owned not-for-profit entities, in micropolitan areas, and in the Southern 
and Western U.S. On the other hand, patients with uncomplicated opioid abuse were 
predominantly of lower-lower income status, metropolitan dwellers, Medicaid covered; and 
presented commonly to privately-owned not-for-profit organizations (though less in proportion 
than opioid dependence case), in metropolitan locations, and in the Northeastern and Midwestern 
United States. 
Regionally, however, the relationship between patient-, hospital-, and state-level policy 
characteristics have not been studied in great detail prior to this study. In the northeastern U.S. 
where all the states in this study had MAT policies, comprehensive MAT medication coverage, 
adopted Medicaid expansion, and more than two-thirds approved Medicaid section 1115 
behavioral health waiver, uncomplicated opioid dependence was the main diagnosis. However, it 
was surprising that more of the patients who were in the higher income bracket, still had 
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Medicaid as their predominant insurer and were mostly treated and released from the ED after 
their uncomplicated OUD diagnosis. In the midwestern region, however, with all states in this 
study having existing MAT policies but with less than three-quarters providing comprehensive 
MAT medication coverage and less than two-thirds haven adopted Medicaid expansion and 
Medicaid section 1115 behavioral health waiver respectively, uncomplicated opioid abuse was 
the predominant diagnosis. It was not surprising that the patients who were mostly low income 
and had Medicaid as their primary payer were typically treated and released post-uncomplicated 
OUD diagnosis in the ED. In contrast, states in the southern region of this study, all of which 
have MAT policies in place but with less than two-thirds providing comprehensive MAT 
medication coverage and just over one-third haven expanded Medicaid and approved the 
Medicaid section 1115 behavioral health waiver respectively, a diagnosis of uncomplicated 
opioid dependence was more preponderant. It was thus not surprising that the patients diagnosed 
and treated for OUD in this region though in the lower income bracket, had the highest 
proportion of self-paying patients and lowest proportion of Medicaid paying patients of all the 
regions. In addition, they were mostly admitted to the same hospital as the ED they were seen. 
Lastly, within the western U.S. in this study, where more than four-fifths had MAT policies, 
comprehensive MAT medication coverage, adopted Medicaid expansion respectively, and just 
less than two-thirds approved Medicaid section 1115 behavioral health waiver, uncomplicated 
opioid dependence was the highest diagnosis of all the regions. It was interesting that the 
proportion of patients in both the lower and higher income brackets was almost evenly split. 
Similarly in this western region of the U.S., about the same number of those patients that were 
treated/released were admitted following the diagnosis of OUD. 
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To our knowledge, this is the first study to show the significant cumulative and individual 
effects of patient-level and hospital-level characteristics on the prevalence of diagnosing and 
treating OUD in the ED in the United States. Specifically, no previous work has attempted to 
highlight the relationship between state-level policy and patient/hospital-level characteristics 
regarding diagnosing and treating OUD in the ED. Prior research, even those that used datasets 
similar to this study, focused on patient-level only, hospital-level only or a combination of 
patient- and hospital-level factors only (Wu et al., 2016; Peterson et al., 2018; Hadland et al., 
2017; Mosher et al., 2017; Gaither et al., 2016; Xie et al., 2014; Chandwani et al., 2013; Mejia et 
al., 2018; Upadhyay et al., 2018; Rivera et al., 2017; Singh et al., 2016; Wall et al., 2015; Wang 
et al., 2015). Additionally, findings from this study revealed over 1,000% increase in the total 
number of ED visits associated with nonmedical use of opioids in the United States between a 
12-year period from 2004 to 2016 (Xie et al, 2014). Also, this study supports the findings of 
prior studies that showed that in spite of enacted state-level policies to address the opioid crisis 
(Blackman, 2017; National Alliance for Model State Drug Laws, 2017; Kaiser Family 
Foundation, 2019; SAMHSA, 2015, 2019), geographic, regional, and other factors still account 
for the rising numbers of patients with OUD visiting the ED (Martin et al., 2016). In addition, 
this study revealed that state-level policies such as the decision by a state to adopt Medicaid 
expansion, hospital-level factor such as the control and ownership of the hospital and its ED, and 
patient-level factor such as where patients are located play more significant roles in determining 
the prevalence of diagnosing and treating OUD in the United States than patient-level 
characteristics like the specific OUD diagnosis or primary payer of the OUD treatment. This may 
be due to issues related to access to and cost of caring for patients with OUD because those who 
really need the care cannot access or pay for it. Furthermore, to avoid the ecological fallacy of 
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using group-level (in this study, hospital-level) findings to make individual-level (in this study, 
patient-level) inferences or its opposite of using individual-level results to inform group-level 
decision making – the atomistic fallacy, a multi-faceted approach needs to be adopted in 
addressing the current opioid crisis. This is demonstrated in this study wherein factors at 
different levels were assessed for their individual influences on the prevalence of diagnosing and 
treating OUD in the ED. 
Unlike prior studies (Chandwani et al., 2013; Mejia et al., 2018; Upadhyay et al., 2018; 
Rivera et al., 2017; Singh et al., 2016; Wall et al., 2015; Wang et al., 2015) however, that 
considered age, gender, and race/ethnicity as contributing factors to the treatment of their 
conditions of interest in the ED, this study did not want to duplicate such works. Thus, only 
patient-level variables – such as primary payer, annual median income, and patient location – 
that could be aggregated to higher levels such as the hospital-level were utilized. This approach 
of aggregating data for use at different levels has been used in previous research (Aiken, et al., 
2018; Wright, et al., 2014; McHugh & Stimpfel, 2012; Claxton, et al., 2015; AHRQ, 2017). 
Similar to previous literature, this study’s findings revealed that total admissions for treatment of 
OUD increased in 2016 (SAMHSA, 2014, 2017, 2018). In addition, however, our study was able 
to provide previously unavailable information about the type of OUD majorly responsible for 
this increase. Our findings indicated that opioid dependence (59.1%) was more significantly 
responsible than opioid abuse (32.8%) for this increase in total admissions for OUD treatment. 
We were also able to show that significantly more patients with opioid abuse (64.7%) than with 
opioid dependence (39.6%) were treated and released from the ED.  
The very low prevalence of diagnosing and treating uncomplicated OUD in the ED in the 
U.S. revealed in this study may be due to patient-related factors – such as fear of stigmatization 
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and reprisals by healthcare workers thus patients with OUD do not present in the ED (Martin et 
al., 2016); provider-related factors – consisting of lack of adequate knowledge, skills, and 
training necessary to treat OUD in the ED (Rubin, 2019; Yang, et al., 2018; Ho & Argáez, 2018; 
Knudsen et al., 2011); system-related factors – including lack of sufficient ED with capabilities 
and resources to treat OUD (Martin et al., 2016), negative attitude and perception of law 
enforcement and the judiciary about patients with OUD leading to incarceration rather than 
assistance; and policy-related factors – comprising dearth of policies for mandating education 
and training for providers to treat OUD, poor reimbursement policies for screening, risk 
assessment, and treatment of OUD particularly in the ED (Martin et al., 2016).  The findings in 
this study that public insurance through Medicare and Medicaid were predominantly responsible 
for paying for OUD treatment followed by private insurance entities then self-paying patient 
aligns with the findings in previous research (Mark et al, 2005; SAMHSA, 2013c). This trend is 
projected to continue in the future with Medicaid playing an increasingly significant role as the 
primary payer for OUD treatment due to continuous expansion and enrollment in Medicaid 
(SAMHSA, 2014a). 
In addition, this study revealed that patients with OUD irrespective of whether the 
specific diagnosis was opioid dependence or opioid abuse presented more at hospital-owned ED 
that were privately owned not-for-profit organizations. Perhaps, these voluntarily controlled 
private ED provide better access to and quality of care including shorter wait times brought 
about by better funding compared to publicly or government-controlled ED thus the attraction 
for patients with OUD. Regarding paying for OUD treatment, it is plausible that Medicaid was 
the major primary payer for patients with opioid abuse because these patients were usually 
younger than 65 years old (SAMHSA, 2010). However, for those patients less than 65 years who 
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did not initiate and/or complete treatment early and aged older than 65 years, Medicare then took 
over paying the cost of their care by which time they may have become opioid dependent. 
Generally, the geographical variations and low markers of financial stability associated with 
patients having OUD highlighted in previous studies (Keyes et al., 2014; Ghertner & Groves, 
2018; Karamouzian & Kerr, 2018; Davenport & Matthews, 2018) have persisted in this study 
findings. However, concerning the relationships between state-level policy, hospital regional and 
socioeconomic characteristics, this study was able to provide new and more detailed information 
described above.  
Strengths and Limitations 
In addition to the conceptualization- and finding-specific strengths highlighted above, 
there are methodological strengths to this study. First, this study utilizes a nationally 
representative dataset – the Nationwide Emergency Department Sample (NEDS) including 
children and adults. Second, this study provides most current estimates. Third, due to the size of 
the dataset, it provides accurate estimates to guide policy and decision-making. Fourth, use of 
hospital-based population allows for focus on specific population of interest and targeting of 
potential interventions (Setia, 2016). Fifth, there is reduction of type I error with the use of HLM 
because HLM bases the sample size it uses for its inferential statistical analysis on the group 
numbers and not the total number of cases. Finally, using HLM allows for separation of within 
group from between-group effects.  
Limitations – NEDS only collected data from noninstitutionalized civilian US population. 
As such, non-civilian and institutionalized population are not included. Therefore, 
generalizability of the findings in this study is limited to noninstitutionalized civilian U.S. 
population only. Second, not all 50 states contributed to the 2016 NEDS, thus only policies 
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specifically within the 35 states of the U.S. and the District of Columbia contributing to the 2016 
NEDS were used in the analysis for this study. Third, the dataset has limited patient variables 
thus restricting the robustness of the analysis. Fourth, generally, HLM is conservative when 
testing level 1 (in this study, patient-level) relationships thus has less power than using the 
generalized linear regression. However, the large sample size in this study addressed this 
limitation.  
Policy Implications 
All stakeholders particularly policy makers at the state-level need to continuously 
evaluate state-level policies and their impact on prevalence of diagnosing and treating OUD in 
the ED. In addition, there is need for continuous monitoring and evaluation of opioid treatment 
programs (OTP) in order to determine their usability and usefulness. Furthermore, there should 
be more funding of hospital-owned ED treatment of OUD (Carney, 2019; Miller, 2019). More 
importantly there is the need for State lawmakers to expedite current multi-sectoral efforts at 
developing novel policies to remedy the crisis (Petruzzelli, 2019). Innovative policies to consider 
include: encouraging alternative approaches such as the emerging non-medication or 
complementary modalities of pain management for patients simultaneously receiving OUD 
treatment (White, 2018; Barry, et al., 2012), expanding ED-based MAT programs (Carney, 2019; 
Miller, 2019), and developing creative reimbursement contracts with stand-alone 
Urgent/Emergency Care Centers to treat OUD. These have become necessary because it is 
possible that more patients with OUD visit other establishments other than the ED to receive 
treatment. 
Health Information Technology Management Practice Implications 
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Regarding health information technology management, there are opportunities for 
creating policies on interoperability and best practices for information sharing (Center for 
Connected Health Policy, 2018). In addition, there are opportunities for using novel approaches 
such as telehealth for caring for patients with OUD since use of telemedicine has been piloted 
and shown to be promising (Rubin, 2019; Yang, et al., 2018; Ho & Argáez, 2018). These are 
imperative because the diagnosis and treatment prevalence of OUD in the ED maybe the result 
of hospitals and their ED still operating in individual silos, not communicating, being 
inaccessible due to their locations or lacking trained healthcare workers capable of prescribing 
for and treating OUD (Rubin, 2019; Yang, et al., 2018; Ho & Argáez, 2018; Knudsen et al., 
2011). Finally, policies related to using these emerging types of care delivery modalities and 
reimbursement for OUD treatment are required (Centers for Medicare and Medicaid Services, 
2019; Savage, 2019). 
Future Research Directions 
In the future, this OUD research will be expanded by creating dose-response models to 
capture incremental effects of varied OUD severity on prevalence of OUD diagnosed and treated 
in the ED. Additionally, the prevalence of OUD among the current study population will be 
quantified to determine potentially preventable cases of OUD by using targeted interventions to 
effectively address the opioid crisis. Furthermore, I will like to examine the association between 
patient, hospital, and state-level policy factors and actual cost (not charges) of caring for 
individuals with OUD in the ED. In addition, I will also want to evaluate through comparative 
analysis whether using MAT to provide treatment for individuals diagnosed with OUD is still 
cost effective and if not, what other approaches may be more cost effective. 
Key Messages 
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• There was more than 1,000% increase in opioid-related incident visits from 144, 600 to 
1,623,490 visits to the emergency departments (ED) in the United States (U.S.) between 
2004 and 2016. 
• There was a 32% increase in ICD-10-CM Diagnostic Codes for opioid-related incidents 
identified in the 2016 NEDS. 
• Uncomplicated opioid use disorder (OUD) – comprising uncomplicated opioid 
dependence and uncomplicated opioid abuse constituted approximately 69% of any 
opioid-related incident ED visit in 2016. 
• Uncomplicated opioid dependence was the more prevalent reason patients with any 
opioid-related incident visited the ED in 2016. 
• More than 1 in 4 patients with uncomplicated opioid dependence were treated in U.S. ED 
in 2016 compared to about 1 in 5 patients with uncomplicated opioid abuse. 
• Targeted interventions at addressing uncomplicated OUD may have potentially reduced 
the opioid crisis by about 50% in 2016. 
• Significant regional disparities still exist between patient-, hospital-, and state-policy 
level characteristics influencing diagnosis and treatment of OUD in U.S. ED. This is in 
spite of existing efforts aimed at addressing the opioid crisis. 
• Socioecological rather than discriminatory and punitive approaches may be required to 
understanding and addressing the opioid crisis. 
• Comprehensive data collected, aggregated, and analyzed at the individual (patient)-level 
and group (interpersonal, organizational, community/environmental, and societal/policy)-
level can potentially improve understanding of factors influencing the current opioid 
crisis. 
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• Continuous quality monitoring, evaluation, and improvement of existing opioid crisis-
related policies are necessary but not sufficient to contain the current opioid crisis, which 
is constantly evolving. 
• High quality data-driven innovative policy creation, decision-making, and resource 
allocation are critical to effectively addressing the current opioid crisis. 
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CONCLUSIONS 
The prevalence of diagnosing and treating opioid use disorder in the emergency 
departments in the United States is very low. This is in spite of the significant rise in the total 
number of ED visits attributable to nonmedical use of opioids in the United States. Overall, a 
combination of patient-level, hospital-level, and state-level policy characteristics can potentially 
significantly influence the prevalence of diagnosing and treating opioid use disorder in the 
emergency departments. However, studied individually, hospital-level characteristics more than 
patient-level characteristics contributed significantly to explaining the variance in the low 
prevalence of caring for opioid use disorder in the emergency departments.  
As such, in addressing the current opioid crisis, a socioecological approach may be 
required such that all levels contributing to this crisis are purposefully and simultaneously 
targeted discretely and in combination. Specifically, individual and group-level factors such as 
interpersonal, organizational, community/environmental and societal characteristics should be 
considered. This ought to be performed with the view to developing innovative policies and 
programs that can positively and significantly address this present opioid crisis. All of these 
efforts should be occurring while existing policies and programs are continuously monitored and 
evaluated for clinical efficiency, cost-effectiveness, quality, and public health impact.  
Approaching the opioid crisis in this manner while not guaranteeing more effective 
decision-making, judicious allocation of scarce resources, and elimination of waste, will almost 
certainly ensure an integrated and holistic method to addressing the crisis. 
 
 
                                                                                                                           97 
 
APPENDICES 
APPENDIX A: Tests of Normality Results 
For PREV_RXOUD_ED: 
 
Case Processing Summary 
 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
Prevalence of treating OUD in 
ED at hospital level 
758835 100.0% 0 0.0% 758835 100.0% 
 
 
Descriptives 
 Statistic Std. Error 
Prevalence of treating OUD in 
ED at hospital level 
Mean .002623987740 .0000031610619 
95% Confidence Interval for 
Mean 
Lower Bound .002617792160  
Upper Bound .002630183310  
5% Trimmed Mean .002205758840  
Median .001958003240  
Variance .000  
Std. Deviation .0027536373300  
Minimum .0000106180  
Maximum .0175897160  
Range .0175790980  
Interquartile Range .0017821477  
Skewness 3.941 .003 
Kurtosis 18.011 .006 
 
 
Tests of Normality 
 
Kolmogorov-Smirnova 
Statistic df Sig. 
Prevalence of treating OUD in ED at hospital level .212 758835 .000 
a. Lilliefors Significance Correction 
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For PREV_RXOUD_Log: 
 
Case Processing Summary 
 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
PREV_RXOUD_ED_Log 758835 100.0% 0 0.0% 758835 100.0% 
 
 
Descriptives 
 Statistic Std. Error 
PREV_RXOUD_ED_Log Mean -2.7133 .00038 
95% Confidence Interval for 
Mean 
Lower Bound -2.7141  
Upper Bound -2.7126  
5% Trimmed Mean -2.7137  
Median -2.7082  
Variance .110  
Std. Deviation .33099  
Minimum -4.97  
Maximum -1.75  
Range 3.22  
Interquartile Range .39  
Skewness -.125 .003 
Kurtosis 2.041 .006 
 
 
Tests of Normality 
 
Kolmogorov-Smirnova 
Statistic df Sig. 
PREV_RXOUD_ED_Log .067 758835 .000 
a. Lilliefors Significance Correction 
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APPENDIX B: Little’s Missing Completely at Random (MCAR) Test Results 
 
MVA 
 
Univariate Statistics 
 N Mean Std. Deviation 
Missing No. of Extremesa 
Count Percent Low High 
PREV_RXOUD_ED_Log 663906 -2.7173 .32974 0 .0 3767 6406 
nDX_OUD 663906   0 .0   
PAY1 663230   676 .1   
ZIPINC_QRTL 643396   20510 3.1   
PL_NCHS 652536   11370 1.7   
EDEVENT 663906   0 .0   
HOSP_CONTROL 663906   0 .0   
HOSP_REGION 663906   0 .0   
HOSP_URCAT4 663906   0 .0   
a. Number of cases outside the range (Mean - 2*SD, Mean + 2*SD). 
 
 
 
EM Estimated Statistics 
 
 
EM Meansa 
PREV_RXOUD_ED_Log 
-2.7180 
a. Little's MCAR test: Chi-Square = 5.434, DF = 1, Sig. = .020 
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APPENDIX C: Hierarchical Linear Model (HLM) Regression and Test of Assumptions Results 
The Hierarchical Linear Model (HLM) regression and test of assumptions results are shown 
below. 
 
Descriptive Statistics 
 Mean Std. Deviation N 
Log Transformation of outcome variable PREV_RXOUD_ED -2.7140 .33005 734627 
String to numeric recode of OUD .56 .497 734627 
Primary expected payer (uniform) 2.28 1.148 734627 
Median household income national quartile for patient ZIP Code 2.23 1.111 734627 
Patient Location: NCHS Urban-Rural Code 2.43 1.423 734627 
Type of ED Event 1.84 5.611 734627 
Control/ownership of hospital .52 1.103 734627 
Region of hospital 2.47 1.117 734627 
Hospital urban-rural designation 1.78 1.478 734627 
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Correlations 
 
Log Transformation of 
outcome variable 
PREV_RXOUD_ED 
String to 
numeric 
recode of 
OUD 
Primary 
expected 
payer 
(uniform) 
Median 
household 
income 
national 
quartile for 
patient ZIP 
Code 
Patient 
Location: 
NCHS 
Urban-
Rural Code 
Type of ED 
Event 
Control/ownership of 
hospital 
Region of 
hospital 
Hospital 
urban-rural 
designation 
Pearson 
Correlation 
Log Transformation of 
outcome variable 
PREV_RXOUD_ED 
1.000 .012 .008 -.032 -.384 -.005 -.402 -.100 -.219 
String to numeric recode 
of OUD 
.012 1.000 -.211 .027 .018 .005 .056 .112 .010 
Primary expected payer 
(uniform) 
.008 -.211 1.000 .018 .014 -.018 -.010 -.015 -.016 
Median household 
income national quartile 
for patient ZIP Code 
-.032 .027 .018 1.000 -.152 .002 -.071 -.070 -.109 
Patient Location: NCHS 
Urban-Rural Code 
-.384 .018 .014 -.152 1.000 -.004 .325 .005 .355 
Type of ED Event -.005 .005 -.018 .002 -.004 1.000 -.009 -.039 -.002 
Control/ownership of 
hospital 
-.402 .056 -.010 -.071 .325 -.009 1.000 .333 .116 
Region of hospital -.100 .112 -.015 -.070 .005 -.039 .333 1.000 .185 
Hospital urban-rural 
designation 
-.219 .010 -.016 -.109 .355 -.002 .116 .185 1.000 
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Sig. (1-tailed) Log Transformation of 
outcome variable 
PREV_RXOUD_ED 
. .000 .000 .000 .000 .000 .000 .000 .000 
String to numeric recode 
of OUD 
.000 . .000 .000 .000 .000 .000 .000 .000 
Primary expected payer 
(uniform) 
.000 .000 . .000 .000 .000 .000 .000 .000 
Median household 
income national quartile 
for patient ZIP Code 
.000 .000 .000 . .000 .058 .000 .000 .000 
Patient Location: NCHS 
Urban-Rural Code 
.000 .000 .000 .000 . .000 .000 .000 .000 
Type of ED Event .000 .000 .000 .058 .000 . .000 .000 .090 
Control/ownership of 
hospital 
.000 .000 .000 .000 .000 .000 . .000 .000 
Region of hospital .000 .000 .000 .000 .000 .000 .000 . .000 
Hospital urban-rural 
designation 
.000 .000 .000 .000 .000 .090 .000 .000 . 
N Log Transformation of 
outcome variable 
PREV_RXOUD_ED 
734627 734627 734627 734627 734627 734627 734627 734627 734627 
String to numeric recode 
of OUD 
734627 734627 734627 734627 734627 734627 734627 734627 734627 
Primary expected payer 
(uniform) 
734627 734627 734627 734627 734627 734627 734627 734627 734627 
Median household 
income national quartile 
for patient ZIP Code 
734627 734627 734627 734627 734627 734627 734627 734627 734627 
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Patient Location: NCHS 
Urban-Rural Code 
734627 734627 734627 734627 734627 734627 734627 734627 734627 
Type of ED Event 734627 734627 734627 734627 734627 734627 734627 734627 734627 
Control/ownership of 
hospital 
734627 734627 734627 734627 734627 734627 734627 734627 734627 
Region of hospital 734627 734627 734627 734627 734627 734627 734627 734627 734627 
Hospital urban-rural 
designation 
734627 734627 734627 734627 734627 734627 734627 734627 734627 
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Variables Entered/Removeda 
Model Variables Entered Variables Removed Method 
1 Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform), 
Patient Location: NCHS Urban-Rural Code, String to numeric recode of OUDb 
. Enter 
2 Region of hospital, Hospital urban-rural designation, Control/ownership of hospitalb . Enter 
a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED 
b. All requested variables entered. 
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Model Summaryc 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .396a .156 .156 .30314 .156 27245.686 5 734621 .000 
2 .504b .254 .254 .28512 .097 31937.906 3 734618 .000 
a. Predictors: (Constant), Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform), Patient Location: NCHS 
Urban-Rural Code, String to numeric recode of OUD 
b. Predictors: (Constant), Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform), Patient Location: NCHS 
Urban-Rural Code, String to numeric recode of OUD, Region of hospital, Hospital urban-rural designation, Control/ownership of hospital 
c. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED 
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ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 12518.475 5 2503.695 27245.686 .000b 
Residual 67506.731 734621 .092   
Total 80025.206 734626    
2 Regression 20307.279 8 2538.410 31226.166 .000c 
Residual 59717.927 734618 .081   
Total 80025.206 734626    
a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED 
b. Predictors: (Constant), Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform), Patient Location: NCHS 
Urban-Rural Code, String to numeric recode of OUD 
c. Predictors: (Constant), Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform), Patient Location: NCHS 
Urban-Rural Code, String to numeric recode of OUD, Region of hospital, Hospital urban-rural designation, Control/ownership of hospital 
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Coefficientsa 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval for 
B Correlations Collinearity Statistics 
B Std. Error Beta Lower Bound Upper Bound Zero-order Partial Part Tolerance VIF 
1 (Constant) -2.450 .001  -1781.271 .000 -2.453 -2.447      
String to numeric recode 
of OUD 
.017 .001 .026 23.976 .000 .016 .019 .012 .028 .026 .954 1.048 
Primary expected payer 
(uniform) 
.006 .000 .021 19.217 .000 .005 .007 .008 .022 .021 .954 1.048 
Median household 
income national quartile 
for patient ZIP Code 
-.028 .000 -.094 -86.365 .000 -.028 -.027 -.032 -.100 -.093 .975 1.025 
Patient Location: NCHS 
Urban-Rural Code 
-.092 .000 -.399 -367.481 .000 -.093 -.092 -.384 -.394 -.394 .976 1.025 
Type of ED Event .000 .000 -.006 -5.431 .000 .000 .000 -.005 -.006 -.006 1.000 1.000 
2 (Constant) -2.443 .002  -1596.472 .000 -2.446 -2.440      
String to numeric recode 
of OUD 
.027 .001 .040 38.940 .000 .026 .028 .012 .045 .039 .941 1.063 
Primary expected payer 
(uniform) 
.005 .000 .018 17.052 .000 .004 .006 .008 .020 .017 .953 1.049 
Median household 
income national quartile 
for patient ZIP Code 
-.031 .000 -.106 -103.329 .000 -.032 -.031 -.032 -.120 -.104 .968 1.033 
Patient Location: NCHS 
Urban-Rural Code 
-.060 .000 -.259 -223.479 .000 -.061 -.060 -.384 -.252 -.225 .754 1.326 
Type of ED Event .000 .000 -.008 -7.588 .000 -.001 .000 -.005 -.009 -.008 .998 1.002 
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Control/ownership of 
hospital 
-.096 .000 -.320 -280.735 .000 -.096 -.095 -.402 -.311 -.283 .780 1.282 
Region of hospital .005 .000 .016 14.066 .000 .004 .005 -.100 .016 .014 .826 1.211 
Hospital urban-rural 
designation 
-.023 .000 -.105 -94.775 .000 -.024 -.023 -.219 -.110 -.096 .833 1.201 
a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED 
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Excluded Variablesa 
Model Beta In t Sig. Partial Correlation 
Collinearity Statistics 
Tolerance VIF 
Minimum 
Tolerance 
1 Control/ownership of hospital -.315b -292.825 .000 -.323 .891 1.122 .877 
Region of hospital -.109b -101.718 .000 -.118 .981 1.020 .941 
Hospital urban-rural designation -.101b -88.292 .000 -.102 .870 1.149 .860 
a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED 
b. Predictors in the Model: (Constant), Type of ED Event, Median household income national quartile for patient ZIP Code, Primary expected payer (uniform), 
Patient Location: NCHS Urban-Rural Code, String to numeric recode of OUD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                           116 
 
Collinearity Diagnosticsa 
Model Dimension Eigenvalue 
Condition 
Index 
Variance Proportions 
(Constant) 
String to 
numeric 
recode of 
OUD 
Primary 
expected 
payer 
(uniform) 
Median 
household 
income 
national 
quartile for 
patient ZIP 
Code 
Patient 
Location: 
NCHS 
Urban-Rural 
Code 
Type of ED 
Event 
Control/ownership 
of hospital 
Region of 
hospital 
Hospital 
urban-rural 
designation 
1 1 4.190 1.000 .00 .02 .01 .01 .01 .01    
2 .883 2.178 .00 .00 .00 .00 .00 .99    
3 .433 3.111 .00 .76 .08 .01 .02 .00    
4 .266 3.968 .00 .00 .02 .24 .60 .00    
5 .178 4.852 .00 .10 .56 .39 .12 .00    
6 .050 9.131 .99 .12 .34 .35 .25 .01    
2 1 5.924 1.000 .00 .01 .00 .00 .00 .00 .01 .00 .01 
2 .909 2.552 .00 .00 .00 .00 .00 .88 .07 .00 .00 
3 .769 2.775 .00 .01 .01 .01 .00 .11 .64 .00 .00 
4 .454 3.614 .00 .63 .02 .00 .02 .00 .01 .00 .15 
5 .380 3.948 .00 .13 .09 .08 .02 .00 .04 .00 .42 
6 .205 5.370 .00 .03 .05 .07 .51 .00 .02 .13 .20 
7 .184 5.676 .00 .03 .29 .53 .07 .00 .01 .10 .00 
8 .138 6.549 .01 .12 .34 .03 .17 .00 .15 .44 .23 
9 .037 12.632 .99 .05 .20 .27 .21 .01 .06 .32 .00 
a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED 
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Residuals Statisticsa 
 Minimum Maximum Mean Std. Deviation N 
Predicted Value -3.4049 -2.4827 -2.7140 .16626 734627 
Std. Predicted Value -4.156 1.391 .000 1.000 734627 
Standard Error of Predicted 
Value 
.000 .006 .001 .000 734627 
Adjusted Predicted Value -3.4048 -2.4827 -2.7140 .16626 734627 
Residual -2.12295 1.11190 .00000 .28511 734627 
Std. Residual -7.446 3.900 .000 1.000 734627 
Stud. Residual -7.446 3.900 .000 1.000 734627 
Deleted Residual -2.12298 1.11193 .00000 .28512 734627 
Stud. Deleted Residual -7.446 3.900 .000 1.000 734627 
Mahal. Distance 1.135 332.138 8.000 17.795 734627 
Cook's Distance .000 .001 .000 .000 734627 
Centered Leverage Value .000 .000 .000 .000 734627 
a. Dependent Variable: Log Transformation of outcome variable PREV_RXOUD_ED 
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